WO2023022497A1 - Sos1 억제제 및 이의 용도 - Google Patents
Sos1 억제제 및 이의 용도 Download PDFInfo
- Publication number
- WO2023022497A1 WO2023022497A1 PCT/KR2022/012254 KR2022012254W WO2023022497A1 WO 2023022497 A1 WO2023022497 A1 WO 2023022497A1 KR 2022012254 W KR2022012254 W KR 2022012254W WO 2023022497 A1 WO2023022497 A1 WO 2023022497A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- stereoisomer
- oxo
- solvate
- pharmaceutically acceptable
- Prior art date
Links
- 229940126271 SOS1 inhibitor Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 209
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 45
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 19
- 230000001404 mediated effect Effects 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 108700022176 SOS1 Proteins 0.000 claims abstract description 10
- 208000029567 RASopathy Diseases 0.000 claims abstract description 3
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims abstract 9
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims abstract 9
- 101150100839 Sos1 gene Proteins 0.000 claims abstract 9
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 491
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 154
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 110
- 229910052736 halogen Inorganic materials 0.000 claims description 79
- 229910052717 sulfur Inorganic materials 0.000 claims description 75
- 229910052799 carbon Inorganic materials 0.000 claims description 71
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 125000005842 heteroatom Chemical group 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 66
- 229910052760 oxygen Inorganic materials 0.000 claims description 64
- 239000012453 solvate Substances 0.000 claims description 58
- 150000002367 halogens Chemical class 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 45
- 125000004043 oxo group Chemical group O=* 0.000 claims description 40
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 37
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 36
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 34
- 229920006395 saturated elastomer Polymers 0.000 claims description 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 20
- 125000004076 pyridyl group Chemical group 0.000 claims description 20
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 19
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 125000001544 thienyl group Chemical group 0.000 claims description 19
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 16
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 16
- 229910052805 deuterium Inorganic materials 0.000 claims description 16
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 15
- 125000002619 bicyclic group Chemical group 0.000 claims description 15
- 229910052731 fluorine Inorganic materials 0.000 claims description 15
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 15
- 125000000335 thiazolyl group Chemical group 0.000 claims description 13
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 10
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 9
- 229910052698 phosphorus Inorganic materials 0.000 claims description 9
- 125000003386 piperidinyl group Chemical group 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000002883 imidazolyl group Chemical group 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 230000007170 pathology Effects 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 7
- 229930192474 thiophene Natural products 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 125000006798 (C1-C6) haloalkylamino group Chemical group 0.000 claims description 5
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 5
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 4
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 208000008723 Capillary malformation-arteriovenous malformation Diseases 0.000 claims description 3
- 201000002927 Cardiofaciocutaneous syndrome Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims description 3
- 208000006286 Legius syndrome Diseases 0.000 claims description 3
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 3
- 125000005458 thianyl group Chemical group 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010067380 Costello Syndrome Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006334 Gingival Fibromatosis Diseases 0.000 claims description 2
- 208000030839 Hereditary gingival fibromatosis Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010029748 Noonan syndrome Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- YUCFVHQCAFKDQG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH] YUCFVHQCAFKDQG-UHFFFAOYSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000000062 kidney sarcoma Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 102100032929 Son of sevenless homolog 1 Human genes 0.000 claims 5
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229910052721 tungsten Inorganic materials 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 26
- 102000004169 proteins and genes Human genes 0.000 abstract description 25
- 239000000126 substance Substances 0.000 abstract description 6
- 102000057028 SOS1 Human genes 0.000 abstract description 5
- 230000003993 interaction Effects 0.000 abstract description 5
- 102000010838 rac1 GTP Binding Protein Human genes 0.000 abstract 1
- 108010062302 rac1 GTP Binding Protein Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 423
- 235000019439 ethyl acetate Nutrition 0.000 description 210
- 239000000203 mixture Substances 0.000 description 196
- 238000003786 synthesis reaction Methods 0.000 description 191
- 239000000543 intermediate Substances 0.000 description 183
- 230000015572 biosynthetic process Effects 0.000 description 180
- 230000002829 reductive effect Effects 0.000 description 180
- 239000011541 reaction mixture Substances 0.000 description 142
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 141
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 137
- 239000012044 organic layer Substances 0.000 description 131
- 238000005481 NMR spectroscopy Methods 0.000 description 127
- 239000011734 sodium Substances 0.000 description 120
- 239000007787 solid Substances 0.000 description 118
- 239000000243 solution Substances 0.000 description 118
- 239000012043 crude product Substances 0.000 description 109
- 239000012267 brine Substances 0.000 description 102
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 102
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 91
- 238000002360 preparation method Methods 0.000 description 89
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 76
- 238000010898 silica gel chromatography Methods 0.000 description 74
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 239000012299 nitrogen atmosphere Substances 0.000 description 54
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 53
- 239000003921 oil Substances 0.000 description 49
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 49
- 239000004698 Polyethylene Substances 0.000 description 48
- 125000001424 substituent group Chemical group 0.000 description 48
- 238000005160 1H NMR spectroscopy Methods 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- 239000000460 chlorine Substances 0.000 description 39
- 239000003208 petroleum Substances 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- 238000002953 preparative HPLC Methods 0.000 description 35
- 102000016914 ras Proteins Human genes 0.000 description 35
- 101150040459 RAS gene Proteins 0.000 description 32
- 101150076031 RAS1 gene Proteins 0.000 description 30
- 238000000746 purification Methods 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 27
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 22
- 239000000706 filtrate Substances 0.000 description 22
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 238000004108 freeze drying Methods 0.000 description 21
- 239000007858 starting material Substances 0.000 description 20
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- 239000010410 layer Substances 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 18
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 17
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 17
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 16
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 16
- 239000007821 HATU Substances 0.000 description 16
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- REYKVZJYIFOXTI-UHFFFAOYSA-N methyl 6-oxo-1h-pyridazine-3-carboxylate Chemical compound COC(=O)C=1C=CC(=O)NN=1 REYKVZJYIFOXTI-UHFFFAOYSA-N 0.000 description 15
- 239000012153 distilled water Substances 0.000 description 14
- 125000000524 functional group Chemical group 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 13
- 150000003840 hydrochlorides Chemical class 0.000 description 13
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
- 230000027455 binding Effects 0.000 description 12
- 239000010949 copper Substances 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 10
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 239000012230 colorless oil Substances 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000010926 purge Methods 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 8
- 239000010936 titanium Substances 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 7
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 7
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 7
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 7
- 229910004298 SiO 2 Inorganic materials 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 7
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 239000011570 nicotinamide Substances 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 102100030708 GTPase KRas Human genes 0.000 description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229910052796 boron Inorganic materials 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 150000003857 carboxamides Chemical class 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 5
- 235000005152 nicotinamide Nutrition 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 description 5
- 125000002098 pyridazinyl group Chemical group 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 description 5
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical group ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 4
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
- LJCYPWAXWYGFOO-UHFFFAOYSA-N 1-[3-nitro-5-(trifluoromethyl)phenyl]ethanone Chemical compound CC(=O)C1=CC([N+]([O-])=O)=CC(C(F)(F)F)=C1 LJCYPWAXWYGFOO-UHFFFAOYSA-N 0.000 description 4
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- YPIPLTBLZPRYGH-CWMRNNLJSA-N CC(C)(C)[S@@](=O)N[C@H](C)C1=CC(=CC(=C1)C(F)(F)F)[N+](=O)[O-] Chemical compound CC(C)(C)[S@@](=O)N[C@H](C)C1=CC(=CC(=C1)C(F)(F)F)[N+](=O)[O-] YPIPLTBLZPRYGH-CWMRNNLJSA-N 0.000 description 4
- PXZRQTXPDLSWEB-UHFFFAOYSA-N CCOC(=O)C(F)(F)C1=C(F)C(=CC=C1)C(C)=O Chemical compound CCOC(=O)C(F)(F)C1=C(F)C(=CC=C1)C(C)=O PXZRQTXPDLSWEB-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 238000007872 degassing Methods 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- PKKHFXIPQXUWGN-UHFFFAOYSA-N methyl 4-hydroxy-6-oxo-1-phenylpyridazine-3-carboxylate Chemical compound O=C1C=C(O)C(C(=O)OC)=NN1C1=CC=CC=C1 PKKHFXIPQXUWGN-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 108010014186 ras Proteins Proteins 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 4
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 4
- RZBQSBXQOWBINI-RXMQYKEDSA-N (1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)c1cc(cc(c1)C(F)(F)F)[N+]([O-])=O RZBQSBXQOWBINI-RXMQYKEDSA-N 0.000 description 3
- LIBZHYLTOAGURM-ZCFIWIBFSA-N (1r)-1-(3-bromophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(Br)=C1 LIBZHYLTOAGURM-ZCFIWIBFSA-N 0.000 description 3
- NJQRAAHKQQPUIT-UHFFFAOYSA-N 1,2-dihydropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CNC1 NJQRAAHKQQPUIT-UHFFFAOYSA-N 0.000 description 3
- DWGRBDDIUAKDIR-UHFFFAOYSA-N 1-(2-fluoro-3-iodophenyl)ethanol Chemical compound FC1=C(C=CC=C1I)C(C)O DWGRBDDIUAKDIR-UHFFFAOYSA-N 0.000 description 3
- GSSUSVIVWXXEDK-UHFFFAOYSA-N 1-(2-fluoro-3-iodophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(I)=C1F GSSUSVIVWXXEDK-UHFFFAOYSA-N 0.000 description 3
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 3
- KLKGUBBTVRHUGD-UHFFFAOYSA-N 1-azido-3-bromobenzene Chemical compound BrC1=CC=CC(N=[N+]=[N-])=C1 KLKGUBBTVRHUGD-UHFFFAOYSA-N 0.000 description 3
- RWDCLDMMTOOIRF-UHFFFAOYSA-N 1-bromo-2-methyl-5-nitro-3-(trifluoromethyl)benzene Chemical compound CC1=C(Br)C=C([N+]([O-])=O)C=C1C(F)(F)F RWDCLDMMTOOIRF-UHFFFAOYSA-N 0.000 description 3
- DMXVRUGSSAPNCE-UHFFFAOYSA-N 1-bromo-3-(difluoromethyl)-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC(C(F)F)=C1 DMXVRUGSSAPNCE-UHFFFAOYSA-N 0.000 description 3
- YDRKGNDUXIXVJU-UHFFFAOYSA-N 1-cyclopropyl-6-oxopyridazine-3-carboxylic acid Chemical compound C1(CC1)N1N=C(C=CC1=O)C(=O)O YDRKGNDUXIXVJU-UHFFFAOYSA-N 0.000 description 3
- MXRJFGJGAKVIJS-UHFFFAOYSA-N 2-fluoro-N,N-dimethyl-3-nitrobenzamide Chemical compound FC1=C(C(=O)N(C)C)C=CC=C1[N+](=O)[O-] MXRJFGJGAKVIJS-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 3
- SPYLLSKIPZGXNM-RXMQYKEDSA-N 3-[(1R)-1-aminoethyl]-5-(trifluoromethyl)aniline Chemical compound C[C@@H](N)c1cc(N)cc(c1)C(F)(F)F SPYLLSKIPZGXNM-RXMQYKEDSA-N 0.000 description 3
- VUOVJDBQQMXYGQ-UHFFFAOYSA-N 3-fluoro-1,2-dimethoxy-4-nitrobenzene Chemical compound COC1=CC=C([N+]([O-])=O)C(F)=C1OC VUOVJDBQQMXYGQ-UHFFFAOYSA-N 0.000 description 3
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 3
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 3
- JSDHUIONSNGZPA-UHFFFAOYSA-N 5-bromo-2-methoxy-n,n-dimethylbenzamide Chemical compound COC1=CC=C(Br)C=C1C(=O)N(C)C JSDHUIONSNGZPA-UHFFFAOYSA-N 0.000 description 3
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 3
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 3
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 3
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 3
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 3
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 3
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 3
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 3
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 3
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010059447 Son of Sevenless Proteins Proteins 0.000 description 3
- 102000005588 Son of Sevenless Proteins Human genes 0.000 description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 230000003281 allosteric effect Effects 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 150000001642 boronic acid derivatives Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- BZHNBNLNJLSPDQ-UHFFFAOYSA-N dimethyl 3-oxo-2-(phenylhydrazinylidene)pentanedioate Chemical compound COC(=O)CC(=O)C(C(=O)OC)=NNC1=CC=CC=C1 BZHNBNLNJLSPDQ-UHFFFAOYSA-N 0.000 description 3
- WSYVBDZLKGUNGB-UHFFFAOYSA-N ethyl 2-(2-ethoxy-2-oxoacetyl)thiophene-3-carboxylate Chemical compound CCOC(=O)C(=O)C=1SC=CC=1C(=O)OCC WSYVBDZLKGUNGB-UHFFFAOYSA-N 0.000 description 3
- JFWUEDOSXNWBII-UHFFFAOYSA-N ethyl 2-(3-acetylphenyl)-2,2-difluoroacetate Chemical compound C(C)(=O)C=1C=C(C=CC=1)C(C(=O)OCC)(F)F JFWUEDOSXNWBII-UHFFFAOYSA-N 0.000 description 3
- RCYLZVUFIMRDLG-UHFFFAOYSA-N ethyl 4-oxo-5h-thieno[2,3-d]pyridazine-7-carboxylate Chemical compound CCOC(=O)C1=NNC(=O)C2=C1SC=C2 RCYLZVUFIMRDLG-UHFFFAOYSA-N 0.000 description 3
- 229960004979 fampridine Drugs 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019988 mead Nutrition 0.000 description 3
- CRGKQFDPUFRQQE-UHFFFAOYSA-N methyl 1-(2,3-difluorophenyl)-6-oxopyridine-3-carboxylate Chemical compound C1=C(C(=O)OC)C=CC(=O)N1C1=CC=CC(F)=C1F CRGKQFDPUFRQQE-UHFFFAOYSA-N 0.000 description 3
- QMFWQVODXGJTJG-UHFFFAOYSA-N methyl 5-bromo-6-oxo-1h-pyridazine-3-carboxylate Chemical compound COC(=O)C=1C=C(Br)C(=O)NN=1 QMFWQVODXGJTJG-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- PXJGUIPZTSDKMY-UHFFFAOYSA-N n-(2-fluoro-5-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC([N+]([O-])=O)=CC=C1F PXJGUIPZTSDKMY-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- LFILDSDQMSCNBV-LURJTMIESA-N propane-2-sulfinamide Chemical compound CC(C)[S@@](N)=O LFILDSDQMSCNBV-LURJTMIESA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical class [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 2
- DQEYVZASLGNODG-ZCFIWIBFSA-N (1r)-1-(3-chlorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(Cl)=C1 DQEYVZASLGNODG-ZCFIWIBFSA-N 0.000 description 2
- YIPGPYIRKCOZJP-MRVPVSSYSA-N (1r)-1-(3-ethoxyphenyl)ethanamine Chemical compound CCOC1=CC=CC([C@@H](C)N)=C1 YIPGPYIRKCOZJP-MRVPVSSYSA-N 0.000 description 2
- JRHPOFJADXHYBR-HTQZYQBOSA-N (1r,2r)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@@H]1CCCC[C@H]1NC JRHPOFJADXHYBR-HTQZYQBOSA-N 0.000 description 2
- JRHPOFJADXHYBR-YUMQZZPRSA-N (1s,2s)-1-n,2-n-dimethylcyclohexane-1,2-diamine Chemical compound CN[C@H]1CCCC[C@@H]1NC JRHPOFJADXHYBR-YUMQZZPRSA-N 0.000 description 2
- SIFCHNIAAPMMKG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) acetate Chemical compound CC(=O)ON1C(=O)CCC1=O SIFCHNIAAPMMKG-UHFFFAOYSA-N 0.000 description 2
- IBTSWKLSEOGJGJ-UHFFFAOYSA-N (3-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=CC(B(O)O)=C1 IBTSWKLSEOGJGJ-UHFFFAOYSA-N 0.000 description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
- YRORYCQXJRYXQB-UHFFFAOYSA-N 1-(2,3-difluorophenyl)-6-oxopyridine-3-carboxylic acid Chemical compound C1=C(C(=O)O)C=CC(=O)N1C1=CC=CC(F)=C1F YRORYCQXJRYXQB-UHFFFAOYSA-N 0.000 description 2
- RUWWFEHTGUJEDT-UHFFFAOYSA-N 1-(3-ethoxyphenyl)ethanone Chemical compound CCOC1=CC=CC(C(C)=O)=C1 RUWWFEHTGUJEDT-UHFFFAOYSA-N 0.000 description 2
- HGAMQOJVZFFXJW-UHFFFAOYSA-N 1-bromo-2-chloro-5-nitro-3-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Br)=C(Cl)C(C(F)(F)F)=C1 HGAMQOJVZFFXJW-UHFFFAOYSA-N 0.000 description 2
- YHTVYRKVFAFVLP-UHFFFAOYSA-N 1-bromo-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC(C(F)(F)F)=C1 YHTVYRKVFAFVLP-UHFFFAOYSA-N 0.000 description 2
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 2
- NNNBRAACNYLATK-SSDOTTSWSA-N 2-[3-[(1R)-1-aminoethyl]phenyl]-2,2-difluoroethanol Chemical compound C[C@@H](N)C1=CC(=CC=C1)C(F)(F)CO NNNBRAACNYLATK-SSDOTTSWSA-N 0.000 description 2
- TUOVLUXPNIFZPC-UHFFFAOYSA-N 2-fluoro-3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(F)=C1OC TUOVLUXPNIFZPC-UHFFFAOYSA-N 0.000 description 2
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 2
- ASKLYHXNJAODLJ-UHFFFAOYSA-N 3-(oxolan-2-yl)aniline Chemical compound NC1=CC=CC(C2OCCC2)=C1 ASKLYHXNJAODLJ-UHFFFAOYSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 2
- LUJMEECXHPYQOF-UHFFFAOYSA-N 3-hydroxyacetophenone Chemical compound CC(=O)C1=CC=CC(O)=C1 LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- AAVYIKIZGPTVFN-UHFFFAOYSA-N 6-oxo-1-phenylpyridazine-3-carboxylic acid Chemical compound N1=C(C(=O)O)C=CC(=O)N1C1=CC=CC=C1 AAVYIKIZGPTVFN-UHFFFAOYSA-N 0.000 description 2
- NGPNYDVHEUXWIA-UHFFFAOYSA-N 6-oxo-1h-pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=C(O)N=C1 NGPNYDVHEUXWIA-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- AJBFNIAEFMBCNS-RXMQYKEDSA-N C1=C(C=C(C=C1C(F)F)N(=O)=O)[C@H](N)C Chemical compound C1=C(C=C(C=C1C(F)F)N(=O)=O)[C@H](N)C AJBFNIAEFMBCNS-RXMQYKEDSA-N 0.000 description 2
- IOHHPDKHBGRCQW-JOCHJYFZSA-N CC(C)(C)[S@@](=O)N=C(C)C1=CC(=CC(=C1)C(F)(F)F)[N+](=O)[O-] Chemical compound CC(C)(C)[S@@](=O)N=C(C)C1=CC(=CC(=C1)C(F)(F)F)[N+](=O)[O-] IOHHPDKHBGRCQW-JOCHJYFZSA-N 0.000 description 2
- PMNIGRUWVXKLSK-ZCFIWIBFSA-N CC1=C(C=C(C=C1C(F)(F)F)[N+](=O)[O-])[C@@H](C)N Chemical compound CC1=C(C=C(C=C1C(F)(F)F)[N+](=O)[O-])[C@@H](C)N PMNIGRUWVXKLSK-ZCFIWIBFSA-N 0.000 description 2
- BYHIODNPEYCJTJ-SSDOTTSWSA-N C[C@@H](N)C1=CC=CC(=C1F)C(F)(F)C(C)(C)O Chemical compound C[C@@H](N)C1=CC=CC(=C1F)C(F)(F)C(C)(C)O BYHIODNPEYCJTJ-SSDOTTSWSA-N 0.000 description 2
- BNYZNPHMICFEFL-ZCFIWIBFSA-N C[C@@H](N)C1=CC=CC(=C1F)C(F)(F)CO Chemical compound C[C@@H](N)C1=CC=CC(=C1F)C(F)(F)CO BNYZNPHMICFEFL-ZCFIWIBFSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ZKNVHJSZNCCXFY-CFMSYZGJSA-N FC(CO)(F)C=1C=C(C=CC=1)[C@@H](C)N[S@](=O)C(C)(C)C Chemical compound FC(CO)(F)C=1C=C(C=CC=1)[C@@H](C)N[S@](=O)C(C)(C)C ZKNVHJSZNCCXFY-CFMSYZGJSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
- 102100029974 GTPase HRas Human genes 0.000 description 2
- 102100039788 GTPase NRas Human genes 0.000 description 2
- 108091006109 GTPases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102100036721 Insulin receptor Human genes 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229930182821 L-proline Natural products 0.000 description 2
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 2
- 101150111783 NTRK1 gene Proteins 0.000 description 2
- 101150117329 NTRK3 gene Proteins 0.000 description 2
- 238000006411 Negishi coupling reaction Methods 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 101150056950 Ntrk2 gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 2
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 2
- UJIXFCWSLWIWBC-UHFFFAOYSA-N [2-(methylaminomethyl)phenyl]boronic acid Chemical compound CNCC1=CC=CC=C1B(O)O UJIXFCWSLWIWBC-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 150000001343 alkyl silanes Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 2
- 229960005061 crizotinib Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 2
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 2
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
- AXAZMDOAUQTMOW-UHFFFAOYSA-N dimethylzinc Chemical compound C[Zn]C AXAZMDOAUQTMOW-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 2
- YYNSXKLGLKOLQZ-UHFFFAOYSA-N ethyl 6-oxo-1h-pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(O)N=C1 YYNSXKLGLKOLQZ-UHFFFAOYSA-N 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- PEGSJNCGPSIJOX-UHFFFAOYSA-N methyl 3-bromothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1Br PEGSJNCGPSIJOX-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 2
- IKJGIOJFOJSYLD-UHFFFAOYSA-N n-(5-amino-2-fluorophenyl)acetamide Chemical compound CC(=O)NC1=CC(N)=CC=C1F IKJGIOJFOJSYLD-UHFFFAOYSA-N 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- HGLFRVLHBJQZME-UHFFFAOYSA-N n-oxopyridine-3-carboxamide Chemical compound O=NC(=O)C1=CC=CN=C1 HGLFRVLHBJQZME-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZVQXQPNJHRNGID-UHFFFAOYSA-N tetramethylsuccinonitrile Chemical compound N#CC(C)(C)C(C)(C)C#N ZVQXQPNJHRNGID-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- SDBJOHCPPBBSMP-UHFFFAOYSA-N (1-acetylpiperidin-4-yl) methanesulfonate Chemical compound CC(=O)N1CCC(OS(C)(=O)=O)CC1 SDBJOHCPPBBSMP-UHFFFAOYSA-N 0.000 description 1
- VLJCJEJRGHGDMQ-UHFFFAOYSA-N (1-methyl-3,6-dihydro-2h-pyridin-4-yl) trifluoromethanesulfonate Chemical compound CN1CCC(OS(=O)(=O)C(F)(F)F)=CC1 VLJCJEJRGHGDMQ-UHFFFAOYSA-N 0.000 description 1
- IVZCHEJTIUBJPM-SCSAIBSYSA-N (1r)-1-(1h-pyrazol-5-yl)ethanamine Chemical compound C[C@@H](N)C1=CC=NN1 IVZCHEJTIUBJPM-SCSAIBSYSA-N 0.000 description 1
- PLIWCUPYMOIFAV-SECBINFHSA-N (1r)-1-(3-chlorophenyl)propan-1-amine Chemical compound CC[C@@H](N)C1=CC=CC(Cl)=C1 PLIWCUPYMOIFAV-SECBINFHSA-N 0.000 description 1
- NYBMETYMNLJOEL-SCSAIBSYSA-N (1r)-1-(5-bromothiophen-2-yl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(Br)S1 NYBMETYMNLJOEL-SCSAIBSYSA-N 0.000 description 1
- DPNRVWDJFMNADR-RXMQYKEDSA-N (1r)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)C1=CC=CC(C(F)(F)F)=C1F DPNRVWDJFMNADR-RXMQYKEDSA-N 0.000 description 1
- ODZXRBRYQGYVJY-ZCFIWIBFSA-N (1r)-1-[3-(trifluoromethyl)phenyl]ethanamine Chemical compound C[C@@H](N)C1=CC=CC(C(F)(F)F)=C1 ODZXRBRYQGYVJY-ZCFIWIBFSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- PENWGQNPFRRVQI-UHFFFAOYSA-N (2-fluorophenyl)hydrazine Chemical compound NNC1=CC=CC=C1F PENWGQNPFRRVQI-UHFFFAOYSA-N 0.000 description 1
- BBENFHSYKBYWJX-UHFFFAOYSA-N (2-formylthiophen-3-yl)boronic acid Chemical compound OB(O)C=1C=CSC=1C=O BBENFHSYKBYWJX-UHFFFAOYSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- MGNBKNBEZGLHNF-UHFFFAOYSA-N (2-methylpyrazol-3-yl)boronic acid Chemical compound CN1N=CC=C1B(O)O MGNBKNBEZGLHNF-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 239000001677 (2R,5R)-1,4-dithiane-2,5-diol Substances 0.000 description 1
- HZFFUMBZBGETES-UHFFFAOYSA-N (3-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC(B(O)O)=C1 HZFFUMBZBGETES-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- LVNPJTSTUBPCMK-UHFFFAOYSA-N (5-chloro-2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=CC=C1C=O LVNPJTSTUBPCMK-UHFFFAOYSA-N 0.000 description 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 description 1
- IOHHPDKHBGRCQW-CAOOACKPSA-N (NE)-2-methyl-N-[1-[3-nitro-5-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide Chemical compound C/C(=N\S(=O)C(C)(C)C)/C1=CC(=CC(=C1)[N+](=O)[O-])C(F)(F)F IOHHPDKHBGRCQW-CAOOACKPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 1
- SNMLKBMPULDPTA-UHFFFAOYSA-N 1,1,1-trifluoropropan-2-amine Chemical compound CC(N)C(F)(F)F SNMLKBMPULDPTA-UHFFFAOYSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- CAVTXAUZYYVGML-UHFFFAOYSA-N 1,2-dihydropyridine-5-carboxamide Chemical compound NC(=O)C1=CNCC=C1 CAVTXAUZYYVGML-UHFFFAOYSA-N 0.000 description 1
- NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical compound B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 1
- YUIOPHXTILULQC-UHFFFAOYSA-N 1,4-Dithiane-2,5-diol Chemical compound OC1CSC(O)CS1 YUIOPHXTILULQC-UHFFFAOYSA-N 0.000 description 1
- MLNVJXISJXMEGE-UHFFFAOYSA-N 1,6-dihydropyridazine-3-carboxylic acid Chemical compound OC(=O)C1=NNCC=C1 MLNVJXISJXMEGE-UHFFFAOYSA-N 0.000 description 1
- HPZLWZKZPAZLIO-UHFFFAOYSA-N 1-(3-chlorophenyl)cyclopropan-1-amine Chemical compound C=1C=CC(Cl)=CC=1C1(N)CC1 HPZLWZKZPAZLIO-UHFFFAOYSA-N 0.000 description 1
- IWLHOUBDKCKJJQ-UHFFFAOYSA-N 1-(3-iodophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(I)=C1 IWLHOUBDKCKJJQ-UHFFFAOYSA-N 0.000 description 1
- KZPIFQYDCVCSDS-UHFFFAOYSA-N 1-(4-hydroxypiperidin-1-yl)ethanone Chemical compound CC(=O)N1CCC(O)CC1 KZPIFQYDCVCSDS-UHFFFAOYSA-N 0.000 description 1
- UVWDMQNZHCWKDY-UHFFFAOYSA-N 1-(5-bromothiophen-3-yl)-n-methylmethanamine Chemical compound CNCC1=CSC(Br)=C1 UVWDMQNZHCWKDY-UHFFFAOYSA-N 0.000 description 1
- GIDGXEUOLBZOMU-UHFFFAOYSA-N 1-[4-amino-6-(trifluoromethyl)pyridin-2-yl]ethanone Chemical compound NC1=CC(=NC(=C1)C(F)(F)F)C(C)=O GIDGXEUOLBZOMU-UHFFFAOYSA-N 0.000 description 1
- QRADKVYIJIAENZ-UHFFFAOYSA-N 1-[[bromo(difluoro)methyl]-ethoxyphosphoryl]oxyethane Chemical compound CCOP(=O)(C(F)(F)Br)OCC QRADKVYIJIAENZ-UHFFFAOYSA-N 0.000 description 1
- DWTJMEQXGJMZMM-UHFFFAOYSA-N 1-bromo-2-chloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(Br)=C1Cl DWTJMEQXGJMZMM-UHFFFAOYSA-N 0.000 description 1
- OYFKTZQGAWXNTI-UHFFFAOYSA-N 1-bromo-2-methyl-3-(trifluoromethyl)benzene Chemical compound CC1=C(Br)C=CC=C1C(F)(F)F OYFKTZQGAWXNTI-UHFFFAOYSA-N 0.000 description 1
- FWIROFMBWVMWLB-UHFFFAOYSA-N 1-bromo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Br)=C1 FWIROFMBWVMWLB-UHFFFAOYSA-N 0.000 description 1
- UOWIYNWMROWVDG-UHFFFAOYSA-N 1-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(C)=O UOWIYNWMROWVDG-UHFFFAOYSA-N 0.000 description 1
- MNBADDMXGOBTIC-UHFFFAOYSA-N 1-fluoro-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(F)=C1OC MNBADDMXGOBTIC-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- OMAFFHIGWTVZOH-UHFFFAOYSA-N 1-methyltetrazole Chemical compound CN1C=NN=N1 OMAFFHIGWTVZOH-UHFFFAOYSA-N 0.000 description 1
- JWAWEQBUZOGIBZ-UHFFFAOYSA-N 1-methyltriazole Chemical compound CN1C=CN=N1 JWAWEQBUZOGIBZ-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HJKLEAOXCZIMPI-UHFFFAOYSA-N 2,2-diethoxyethanamine Chemical compound CCOC(CN)OCC HJKLEAOXCZIMPI-UHFFFAOYSA-N 0.000 description 1
- YCCQGFYAVUTQFK-UHFFFAOYSA-N 2,3-difluoroaniline Chemical compound NC1=CC=CC(F)=C1F YCCQGFYAVUTQFK-UHFFFAOYSA-N 0.000 description 1
- SSDAKJLEKSSAMH-UHFFFAOYSA-N 2,4-dihydro-1h-pyridazin-3-one Chemical group O=C1CC=CNN1 SSDAKJLEKSSAMH-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
- IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- PJINTMYHQOGFTQ-UHFFFAOYSA-N 2-fluoro-3-iodobenzaldehyde Chemical compound FC1=C(I)C=CC=C1C=O PJINTMYHQOGFTQ-UHFFFAOYSA-N 0.000 description 1
- WLGUSLGYTNJJFV-UHFFFAOYSA-N 2-fluoro-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1F WLGUSLGYTNJJFV-UHFFFAOYSA-N 0.000 description 1
- YWUVOJJHVFLNJA-UHFFFAOYSA-N 2-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C(F)=C1 YWUVOJJHVFLNJA-UHFFFAOYSA-N 0.000 description 1
- KJVBJICWGQIMOZ-UHFFFAOYSA-N 2-fluoro-5-nitroaniline Chemical compound NC1=CC([N+]([O-])=O)=CC=C1F KJVBJICWGQIMOZ-UHFFFAOYSA-N 0.000 description 1
- ILPWEAHQRAWJIU-OAHLLOKOSA-N 2-methyl-3-[(1R)-1-[(4-methyl-7-morpholin-4-ylpyrido[3,4-d]pyridazin-1-yl)amino]ethyl]benzonitrile Chemical compound C[C@@H](NC1=NN=C(C)C2=CN=C(C=C12)N1CCOCC1)C1=CC=CC(C#N)=C1C ILPWEAHQRAWJIU-OAHLLOKOSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- RQPKSOWRJPRYCN-UHFFFAOYSA-N 3-(4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-2-yl)aniline Chemical compound NC1=CC=CC(C=2N=C3C4=CC=CN=C4OC3=C(N3CCOCC3)N=2)=C1 RQPKSOWRJPRYCN-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- HAHYXYKFMHJMIE-UHFFFAOYSA-N 3-azabicyclo[2.1.1]hexane Chemical compound C1C2CC1CN2 HAHYXYKFMHJMIE-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OUDCOMBHRXKPIJ-UHFFFAOYSA-N 3-bromo-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC(Br)=CC(C=O)=C1 OUDCOMBHRXKPIJ-UHFFFAOYSA-N 0.000 description 1
- NQVWMPOQWBDSAI-UHFFFAOYSA-N 3-methyloxetan-3-amine Chemical compound CC1(N)COC1 NQVWMPOQWBDSAI-UHFFFAOYSA-N 0.000 description 1
- OXTNCQMOKLOUAM-UHFFFAOYSA-L 3-oxopentanedioate Chemical compound [O-]C(=O)CC(=O)CC([O-])=O OXTNCQMOKLOUAM-UHFFFAOYSA-L 0.000 description 1
- RNJOKCPFLQMDEC-UHFFFAOYSA-N 4(R),8-dimethyl-trans-2-nonenoyl-CoA Chemical compound COC(=O)CC(=O)CC(=O)OC RNJOKCPFLQMDEC-UHFFFAOYSA-N 0.000 description 1
- IARROBNTXKAFNV-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(4-methyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane Chemical compound CC1OB(OC1)B1OC(C(O1)(C)C)(C)C IARROBNTXKAFNV-UHFFFAOYSA-N 0.000 description 1
- NLTIETZTDSJANS-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NC=C1 NLTIETZTDSJANS-UHFFFAOYSA-N 0.000 description 1
- GMHHTGYHERDNLO-UHFFFAOYSA-N 4-bromobicyclo[4.2.0]octa-1(6),2,4-triene Chemical compound BrC1=CC=C2CCC2=C1 GMHHTGYHERDNLO-UHFFFAOYSA-N 0.000 description 1
- IVBVKTPDEWDNRW-UHFFFAOYSA-N 4-bromooxane Chemical compound BrC1CCOCC1 IVBVKTPDEWDNRW-UHFFFAOYSA-N 0.000 description 1
- XILPCSMEKCBYFO-UHFFFAOYSA-N 4-methyl-1,2,4-triazole Chemical compound CN1C=NN=C1 XILPCSMEKCBYFO-UHFFFAOYSA-N 0.000 description 1
- NZZWXNMQOCNDKD-UHFFFAOYSA-N 5-bromo-1,3-dihydro-2-benzofuran Chemical compound BrC1=CC=C2COCC2=C1 NZZWXNMQOCNDKD-UHFFFAOYSA-N 0.000 description 1
- JFDUXZIRWBYBAQ-UHFFFAOYSA-N 5-bromo-2-methoxybenzoic acid Chemical compound COC1=CC=C(Br)C=C1C(O)=O JFDUXZIRWBYBAQ-UHFFFAOYSA-N 0.000 description 1
- HMVGGGOWCWNMNY-UHFFFAOYSA-N 5-bromo-2-methyl-1,3-thiazole Chemical compound CC1=NC=C(Br)S1 HMVGGGOWCWNMNY-UHFFFAOYSA-N 0.000 description 1
- ZKLBPUYMTHPNOQ-UHFFFAOYSA-N 5-bromothiophene-3-carbaldehyde Chemical compound BrC1=CC(C=O)=CS1 ZKLBPUYMTHPNOQ-UHFFFAOYSA-N 0.000 description 1
- YVKMCSMHVJNAAM-UHFFFAOYSA-N 6-oxo-1-phenyl-4,5-dihydropyridazine-3-carboxylic acid Chemical compound O=C1CCC(C(=O)O)=NN1C1=CC=CC=C1 YVKMCSMHVJNAAM-UHFFFAOYSA-N 0.000 description 1
- XBQRGTPJNIKNIB-UHFFFAOYSA-N 6-oxo-1h-pyridazine-3-carboxamide Chemical compound NC(=O)C=1C=CC(=O)NN=1 XBQRGTPJNIKNIB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229940125795 BI-3406 Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ALNYFEPTXWICHS-UHFFFAOYSA-N CC(=O)C1=CC=CC(=C1F)C(F)(F)C(C)(C)O Chemical compound CC(=O)C1=CC=CC(=C1F)C(F)(F)C(C)(C)O ALNYFEPTXWICHS-UHFFFAOYSA-N 0.000 description 1
- SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000004626 Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 108010003384 Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- TXIXSLPEABAEHP-UHFFFAOYSA-N Dimethyl 2-oxoglutarate Chemical compound COC(=O)CCC(=O)C(=O)OC TXIXSLPEABAEHP-UHFFFAOYSA-N 0.000 description 1
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
- 239000012824 ERK inhibitor Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 108091009389 Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101000580039 Homo sapiens Ras-specific guanine nucleotide-releasing factor 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000868154 Homo sapiens Son of sevenless homolog 2 Proteins 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012819 MDM2-Inhibitor Substances 0.000 description 1
- 229940126270 MRTX0902 Drugs 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 102100027551 Ras-specific guanine nucleotide-releasing factor 1 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 102100032930 Son of sevenless homolog 2 Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910007926 ZrCl Inorganic materials 0.000 description 1
- QFRSVPDEEDBLOS-UHFFFAOYSA-N [3-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]phenyl]boronic acid Chemical compound CC(C)(C)OC(=O)N(C)C1=CC=CC(B(O)O)=C1 QFRSVPDEEDBLOS-UHFFFAOYSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- 229960001611 alectinib Drugs 0.000 description 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- UMIVXZPTRXBADB-UHFFFAOYSA-N benzocyclobutene Chemical compound C1=CC=C2CCC2=C1 UMIVXZPTRXBADB-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- RPZUBXWEQBPUJR-UHFFFAOYSA-N bicyclo[4.2.0]octane Chemical compound C1CCCC2CCC21 RPZUBXWEQBPUJR-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 208000014729 capillary malformation Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- LYZCWDIVOAXKQP-UHFFFAOYSA-N diazinan-3-one Chemical group O=C1CCCNN1 LYZCWDIVOAXKQP-UHFFFAOYSA-N 0.000 description 1
- GRTGGSXWHGKRSB-UHFFFAOYSA-N dichloromethyl methyl ether Chemical compound COC(Cl)Cl GRTGGSXWHGKRSB-UHFFFAOYSA-N 0.000 description 1
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-M difluoroacetate Chemical compound [O-]C(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-M 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005435 dihydrobenzoxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000005072 dihydrothiopyranyl group Chemical group S1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229950000521 entrectinib Drugs 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- FCECBOGDWDCVLU-XMMPIXPASA-N ethyl 2-[3-[N-[(R)-tert-butylsulfinyl]-C-methylcarbonimidoyl]-2-fluorophenyl]-2,2-difluoroacetate Chemical compound CCOC(=O)C(C1=CC=CC(=C1F)C(=N[S@](=O)C(C)(C)C)C)(F)F FCECBOGDWDCVLU-XMMPIXPASA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 101150098203 grb2 gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-O hydron;tricyclohexylphosphane Chemical compound C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-O 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 229940125399 kras g12c inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- VNFXNPFSTYYFCZ-UHFFFAOYSA-N methyl 6-oxo-1h-pyrazine-3-carboxylate Chemical compound COC(=O)C1=CN=C(O)C=N1 VNFXNPFSTYYFCZ-UHFFFAOYSA-N 0.000 description 1
- HHWWWZQYHPFCBY-UHFFFAOYSA-N methyl 6-oxopyran-3-carboxylate Chemical compound COC(=O)C=1C=CC(=O)OC=1 HHWWWZQYHPFCBY-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108091005763 multidomain proteins Proteins 0.000 description 1
- XOJAPHKOMSHQEI-UHFFFAOYSA-N n-(3-bromophenyl)cyclopropanecarboxamide Chemical compound BrC1=CC=CC(NC(=O)C2CC2)=C1 XOJAPHKOMSHQEI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 description 1
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 230000009125 negative feedback regulation Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960004390 palbociclib Drugs 0.000 description 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- PSBAIJVSCTZDDB-UHFFFAOYSA-N phenyl acetylsalicylate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 PSBAIJVSCTZDDB-UHFFFAOYSA-N 0.000 description 1
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000005299 pyridinones Chemical group 0.000 description 1
- 125000005494 pyridonyl group Chemical group 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 1
- 229940073531 sotorasib Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 1
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical class OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 description 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229950008878 ulixertinib Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a novel compound having SOS1 inhibitory activity, a solvate thereof, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating diseases comprising the same as an active ingredient, and a pharmaceutical use thereof .
- RAS-family proteins include KRAS, NRAS or HRAS.
- the RAS protein is a small GTPase that exists in cells in either a GTP-bound or GDP-bound state, and is a molecular switch that cycles between an active GTP-bound state and an inactive GDP-bound state. Mutations in the RAS gene reduce the ability of the GTPase RAS to hydrolyze GTP, allowing this molecular switch to maintain a constitutively active GTP-bound conformation, thereby enabling oncogenic downstream signaling (e.g., the Raf-MEK-ERK pathway or PI3K pathway). -PDK1-Akt pathway).
- oncogenic downstream signaling e.g., the Raf-MEK-ERK pathway or PI3K pathway.
- GAPs GTPase activating proteins
- NF1 GTPase activating proteins
- GEFs guanine nucleotide exchange factors
- Son of Sevenless 1 is a type of guanine nucleotide exchange factor (GEF), which regulates RAS family protein signaling by facilitating GTP binding by promoting the release of GDP by RAS family proteins.
- GEF guanine nucleotide exchange factor
- Son of Sevenless (SOS) protein exists in two isoforms, SOS1 and SOS2, and only SOS1 is phosphorylated by ERK. Growth factor-induced phosphorylation of SOS1 is mostly mediated by ERK, which phosphorylates at least four serine residues in the C-terminal region of SOS1. This suggests that SOS1 plays an important role in negative feedback regulation of the KRAS pathway.
- the SOS1 protein consists of 1333 amino acids (150 kDa).
- SOS1 consists of two tandem N-terminal histone domains (HD) followed by a Dbl homology domain (DH), a pleckstrin homology domain (PH), a helical linker (HL), a RAS exchange motif (REM), a CDC25 homology domain and It is a multidomain protein with a C-terminal proline rich domain (PR).
- SOS1 has two binding sites for RAS family proteins (i.e., a catalytic site that binds GDP-binding RAS family proteins and promotes exchange of guanine nucleotides, and a catalytic site activity of SOS1 by binding GTP-binding RAS family proteins). upregulating allosteric sites) (J. Med. Chem. 2021, 64, 10, 6569-6580).
- Selective pharmacological inhibition of SOS1's catalytic site binding to RAS family proteins is expected to prevent SOS1-mediated activation of RAS-family proteins in a GTP-bound form.
- SOS1 inhibitor compounds are expected to inhibit signaling (eg, ERK phosphorylation) in subcellular cells of RAS-family proteins, novel SOS1 that binds to the SOS1 catalytic site and prevents binding to and activation of RAS-family proteins. Inhibitor compounds are being developed.
- signaling eg, ERK phosphorylation
- SOS1 is critically involved in mutant KRAS activation and oncogenic signaling in cancer (Current Opinion in Chemical Biology, 2021, 62: 109-118). Depletion of SOS1 levels reduced survival of tumor cells harboring KRAS mutations, but no such effect was observed in KRAS wild-type cell lines. The SOS1 depletion effect cannot be rescued by the SOS1 F929A mutation in which the catalytic site is damaged or the SOS1 mutation in which GTP-KRAS binding is defective at the allosteric site (SOS1 L687E/R688A ), which cannot be rescued by the catalytic site or allosteric site of SOS1. This suggests that site targeting could be an effective option for the treatment of KRAS mutant cancers.
- SOS1 is critically involved in the activation of RAS family protein signaling in cancer through mechanisms other than mutation of RAS family proteins.
- SOS1 interacts with the adapter protein Grb2 to form the SOS1/Grb2 complex.
- the complex is activated/phosphorylated receptor tyrosine kinase (e.g., EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A/B, FGFR1/2/3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c -MET, VEGFR1/2/3, AXL).
- SOS1 has also been reported to localize to other phosphorylated cell surface receptors such as T cell receptor (TCR), B cell receptor (BCR) and monocyte colony stimulating factor receptor, consequently activating RAS family proteins.
- TCR T cell receptor
- BCR B cell receptor
- monocyte colony stimulating factor receptor consequently activating RAS family proteins.
- SOS1 is a GEF for activation of the GTPase RAC1 (Ras-associated C3 botulinum toxin substrate 1).
- RAC1 Ras-associated C3 botulinum toxin substrate 1
- RAS-family proteins Ras-associated C3 botulinum toxin substrate 1
- BI-3406, BI-1701963, MRTX0902, etc. are being developed as SOS1 activity inhibitors, but they are still in the early stages of development, and the development of new compounds for treating cancer by inhibiting SOS1 and pharmaceutical compositions containing them is still required in the art It is becoming.
- Another object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a method for preventing or treating SOS1 mediated diseases by administering a compound of Formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.
- One aspect of the present invention provides a compound, solvate, stereoisomer or pharmaceutically acceptable salt of Formula 1 below.
- E is O or S
- X is O or S
- Z 1 is N or CH
- Z 2 is N, NH
- Z 3 is CR 1 or CHR 1 and at most one of Z 1 , Z 2 and Z 3 is N or NH;
- each R 1 is independently H, halogen, OH, CN, NR b R c , C 1 -C 6 alkyl optionally interrupted and/or optionally substituted with 1 to 3 oxygen atoms or nitrogen atoms, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 1 -C 6 acylamino, optionally substituted (C 1 -C 6 alkyl)sulfonylamino , optionally substituted C 3 -C 6 cycloalkyl, optionally substituted 4-7 membered heterocycloalkyl, optionally substituted C 6 -C 10 aryl, optionally substituted C 6 -C 10 aryloxy, optionally substituted (C 6 -C 10 aryl)-(C 1 -C 6 alkyl)oxy-, optionally substituted (C 6 -C 10 aryl)amin
- Z 1 is N; is a double bond, and when Z 2 and Z 3 are both CR 1 , two R 1s are optionally linked to each other to form a 5-membered heteroaryl containing one N, O or S together with the carbon atom to which they are bonded; ;
- R′ and R′′ are each independently H or C 1 -C 3 alkyl, or R′ and R′′ bonded to the same carbon or adjacent carbon atoms together with the carbon atom to which they are attached form C 3 -C 4 cycloalkyl. wherein the C 1 -C 3 alkyl and C 3 -C 4 cycloalkyl may be optionally substituted with one or more halogen, OH, CN, C 1 -C 3 alkoxy or NR b R c ;
- n is an integer from 1 to 3;
- A is Cy 1 or Cy 1 -Y-Cy 2 ;
- Y is NR d , CR d R e , O, S, or a direct key
- Cy 1 and Cy 2 are each independently a C 6 -C 10 aryl optionally fused with a C 3 -C 8 cycloalkyl, or a 5- to 10-membered heteroaryl;
- Said Cy 1 and Cy 2 may each be optionally substituted with 1 to 3 R 2 ;
- B is H, optionally substituted C 1- C 6 alkyl, -(CH 2 ) o -Cy 3 or -(CH 2 ) o -Cy 3 -W-Cy 4 ;
- o is an integer from 0 to 3;
- W is NR d , CR d R e , C(O), O, S, or a direct key
- Cy 3 and Cy 4 are each independently a C 3 -C 6 monocyclic cycloalkyl or C 3 -C 6 monocyclic cycloalkyl optionally fused with a 5- to 10-membered heterocycloalkyl or a 5- to 10- membered heteroaryl.
- alkenyl bicyclic, tricyclic or tetracyclic bridged, fused or spiro C 5 -C 20 cycloalkyl or C 5 -C 20 cycloalkenyl; C 6 -C 10 aryl optionally fused with a 5- to 10-membered heterocycloalkyl; 5- to 10-membered monocyclic heteroaryl optionally fused with C 3 -C 6 cycloalkyl; 5- to 10-membered bicyclic heteroaryl; 4- to 10-membered saturated or partially unsaturated monocyclic heterocycloalkyl, optionally fused with C 3 -C 6 cycloalkyl; and 5- to 10-membered bicyclic bridged, fused or spiro heterocycloalkyl;
- Cy 3 and Cy 4 may each independently be optionally substituted with 1 to 3 R 3 ;
- R b and R c are each independently H or optionally substituted C 1 -C 6 alkyl
- R d and R e are each independently H or optionally substituted C 1 -C 6 alkyl.
- substituent definition may mean that the structure is optionally substituted with one or more substituents selected from the group consisting of:
- C 3 -C optionally substituted with one or more substituents selected from the group consisting of halogen, OH, CN, oxo, NH 2 , NH(C 1- C 6 alkyl) and N(C 1- C 6 alkyl) 2 6 cycloalkyl.
- the optionally substituted moiety is composed of halogen, OH, CN, NH 2 , NH(C 1- C 6 alkyl), N(C 1- C 6 alkyl) 2 and C 1 -C 3 alkoxy. may be substituted with one or more identical or different substituents selected from the group.
- an “optionally substituted” group is deuterium, halogen, OH, CN, oxo, amino, C 1- C 6 alkylamino, di(C 1- C 6 alkyl)amino, C 1- C 6 haloalkyl, It may be unsubstituted or substituted with one or more substituents selected from the group consisting of C 1 -C 6 hydroxyalkyl, C 1 -C 6 cyanoalkyl, C 1 -C 6 aminoalkyl and C 1 -C 6 alkoxy. In this case, two or more substituents may be substituted on the same atom or on different atoms.
- 1-fluoro-2-oxopropyl is included within “optionally substituted alkyl” of this disclosure as an alkyl group in which oxo and fluoro are substituted on different carbon atoms of the propyl group, respectively.
- substituents when two or more substituents are substituted on the same moiety, they may be substituted on the same atom or different atoms of the moiety.
- E may be O or S, for example, E may be O.
- X may be O or S.
- X may be O.
- Z 1 may be N or CH
- Z 2 may be N
- NH CR 1 or CHR 1
- Z 3 may be CR 1 or CHR 1 .
- one or less of Z 1 , Z 2 and Z 3 is N or NH.
- Z 1 is N; is a double bond, and when Z 2 and Z 3 are both CR 1 , two R 1s are optionally linked to each other to form a 5-membered heteroaryl ring containing 1 N, O or S together with the carbon atom to which they are attached. can do.
- m may be an integer of 1 to 3, for example, m may be 1 or 2. In one embodiment, m may be 1. When m is 2 or 3, R' bonded to each carbon of the alkylene chain may be the same as or different from each other. When m is 2 or 3, R'' bonded to each carbon of the alkylene chain may be the same as or different from each other.
- R' and R′′ are each independently H or C 1-3 alkyl, such as -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH(CH 3 ) 2 can be
- the C 1 -C 3 alkyl may be optionally substituted with one or more halogen, OH, CN, C 1 -C 3 alkoxy or NR b R c , in which case R b and R c are each independently H or optionally substituted C 1 -C 3 alkyl.
- both R' and R′′ can be C 1-3 alkyl.
- both R' and R'' can be H.
- one of R' and R′′ can be H and the other can be C 1-3 alkyl.
- one of R' and R'' is H, and the other is methyl, ethyl, difluoromethyl, fluoromethyl, hydroxymethyl, aminomethyl, etc., but is not limited thereto.
- R′ and R′′ bonded to the same carbon or adjacent carbons together with the carbon atoms to which they are bonded may form a cyclopropyl or cyclobutyl ring.
- the cyclopropyl or cyclobutyl ring may be optionally substituted with one or more halogen, OH, CN, C 1 -C 3 alkoxy or NR b R c , in which case R b and R c are each independently H or optionally substituted C 1 -C 3 alkyl.
- R' and R'' together with the alkylene chain to which they are attached may form the following structure, but is not limited thereto:
- R 1 is H, halogen, OH, CN, NR b R c , C 1 -C 6 alkyl optionally interrupted by 1 to 3 oxygen atoms or nitrogen atoms, optionally substituted C 1 -C 6 alkyl, Optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 1 -C 6 acylamino, optionally substituted (C 1 - C 6 alkyl)sulfonylamino, or C 3 -C 6 cycloalkyl.
- R 1 is an optionally substituted C 1 -C 6 alkyl, an optionally substituted C 2 -C 6 alkenyl, or an optionally substituted C 2 -C 6 alkynyl, preferably an optionally substituted C 1 - C 3 alkyl.
- an optionally substituted C 1 -C 6 alkyl or C 1 -C 3 alkyl, an optionally substituted C 2 -C 6 alkenyl, or an optionally substituted C 2 -C 6 alkynyl is selected from the above substituents (i) to ( iv) may be substituted with one or more substituents selected from the group consisting of.
- the one or more substituents are a combination of two or more substituents selected from any one of (i), (ii), (iii) and (iv) or two of (i), (ii), (iii) and (iv) It may include a combination of two or more substituents each selected from the above, or a combination thereof, and when the substituents are two or more, they may be different from or the same as each other.
- optionally substituted C 1 -C 6 alkyl or C 1 -C 3 alkyl is substituted with 1 to 5, 1 to 4, 1 to 3, 1, 2 or 3 substituents. It may include, for example, -CF 2 CH 2 OH substituted with 2 F and 1 OH, -CF 3 substituted with 3 F, and the like.
- the C 1 -C 6 alkyl may be optionally interrupted by 1 to 3 oxygen atoms or nitrogen atoms, such as methoxymethyl, methoxymethoxymethyl, ethoxymethyl, ethoxyethoxymethyl, methylaminomethyl, methyl aminoethyl, dimethylaminomethyl, dimethylaminoethyl, and the like.
- R 1 is an optionally substituted 4- to 7-membered heterocycloalkyl, an optionally substituted C 6 -C 10 aryl, an optionally substituted C 6 -C 10 aryloxy, an optionally substituted (C 6 -C 10 aryl)-(C 1 -C 6 alkyl)oxy-, optionally substituted (C 6 -C 10 aryl)amino or optionally substituted 5- to 10-membered heteroaryl.
- the substituents that can be optionally substituted are as described above.
- R 1 can be a 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O and S, such as azetidinyl, oxetanyl, pyrrolidinyl , tetrahydrofuranyl, piperidinyl or piperazinyl, but is not limited thereto.
- R 1 is a 5- to 10-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S, such as but not limited to indolyl, pyridinyl, pyrimidinyl, pyrazinyl.
- R 1 can be phenyl or naphthyl.
- A may be Cy 1 or Cy 1 -Y-Cy 2 .
- Y may be NR d , CR d R e , O, S, or a direct bond.
- R d and R e may each be H or optionally substituted C 1 -C 6 alkyl, preferably H or optionally substituted C 1 -C 3 alkyl. At this time, the substituent that can be optionally substituted is as described above.
- Cy 1 and Cy 2 may each independently be a C 6 -C 10 aryl, a C 3 -C 8 cycloalkyl-fused C 6 -C 10 aryl, or a 5- to 10-membered heteroaryl. there is.
- the Cy 1 may be C 6 -C 10 aryl or a 5- to 6-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, or S. In one embodiment, Cy 1 can be C 6 -C 10 aryl. In other embodiments, Cy 1 can be a 5-6 membered heteroaryl containing 1 or 2 N or S.
- Cy 1 can include phenyl, naphthalenyl, thiazolyl, thiophenyl or pyrazolyl.
- Cy 2 is C 6 -C 10 aryl fused with C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, or 5 containing 1 to 3 heteroatoms of N, O or S It may be a one- to six-membered heteroaryl.
- Cy 2 can be a C 6 -C 10 aryl fused with a C 3 -C 5 cycloalkyl, or a C 6 -C 10 aryl.
- Cy 2 can be a 5-6 membered heteroaryl containing 1 or 2 N or S.
- Cy 2 is phenyl, 2,3-dihydroindenyl or bicyclo[4.2.0]octa-1,3,5-trienyl, pyrazolyl, thiophenyl, pyridinyl, 2-oxo-1 ,2-dihydropyridinyl or pyrrolyl.
- A is Cy 1 and Cy 1 can be C 6 -C 10 aryl, such as phenyl or naphthyl. In some embodiments, A is Cy 1 , and Cy 1 can be a 5-10 membered heteroaryl. In some embodiments, A can be Cy 1 -Y-Cy 2 , Cy 1 and Cy 2 can each be C 6 -C 10 aryl, and Y can be O. For example, A can be phenyl-O-phenyl. In some embodiments, A is Cy 1 -Y-Cy 2 , Cy 1 is C 6 -C 10 aryl, and Cy 2 can be a 5- to 10-membered heteroaryl. In some embodiments, A is Cy 1 -Y-Cy 2 , Cy 1 is a 5- to 10-membered heteroaryl, and Cy 2 can be C 6 -C 10 aryl.
- the 5- to 10-membered heteroaryl of Cy 1 or Cy 2 is indolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiophenyl, pyrazolyl, oxazolyl, isoxa zolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, imidazolyl, or triazolyl.
- each of Cy 1 and Cy 2 may be optionally substituted with 1 to 3 R 2 .
- specific substituents of R 2 are as described in Formula I below.
- Cy 1 when A is Cy 1 -Y-Cy 2 , in this case, Cy 1 may be optionally substituted with 1 to 3 R 2a , and Cy 2 is optionally substituted with 1 to 3 R 2b . may be optionally substituted.
- R 2a and R 2b are as described in Formula I below.
- B may be H, optionally substituted C 1 -C 6 alkyl, -(CH 2 ) o -Cy 3 or -(CH 2 ) o -Cy 3 -W-Cy 4 .
- o may be an integer from 0 to 3. Also, o may be 0 or 1.
- B can be -(CH 2 ) o -Cy 3 . In some embodiments, B can be -(CH 2 ) o -Cy 3 -W-Cy 4 .
- W can be NR d , CR d R e , O, S, or a direct bond, and R d and R e are each H or optionally substituted C 1 -C 6 alkyl, preferably H or optionally substituted may be C 1 -C 3 alkyl.
- the substituent that can be optionally substituted is as described above.
- Cy 3 and Cy 4 are each independently C 3 -C 6 monocyclic cycloalkyl or C 3 -C 6 monocyclic cycloalkenyl, and the cycloalkyl or cycloalkenyl is 5
- a 1 to 10 membered heterocycloalkyl or a 5 to 10 membered heteroaryl may optionally be fused.
- Cy 3 and Cy 4 are each independently cyclopropyl; cyclobutyl, cyclopentyl, cyclohexyl; cyclobutenyl; cyclopentenyl, cyclohexenyl; It may be cyclohexyl or cyclopentyl, fused with pyrazole, piperazine or tetrahydropyran.
- the 5- to 10-membered heteroaryl fused to the cycloalkyl or cycloalkenyl is indolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, imidazolyl, or triazolyl.
- the 5- to 10-membered heterocycloalkyl fused to the cycloalkyl or cycloalkenyl includes tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydro 2H-thiopyranyl, Not limited to this.
- Cy 3 and Cy 4 can each independently be a bicyclic, tricyclic or tetracyclic bridge, fused or spiro C 5 -C 20 cycloalkyl or C 5 -C 20 cycloalkenyl. In one embodiment, Cy 3 and Cy 4 can each independently be a bicyclic or tricyclic bridge or fused C 5 -C 15 cycloalkyl or C 5 -C 15 cycloalkenyl. In one embodiment, Cy 3 can be a bicyclic or tricyclic bridged C 5 -C 10 cycloalkyl or C 5 -C 10 cycloalkenyl.
- the Cy 3 is bicyclo[2.2.2]octanyl, adamantyl, bicyclo[2.2.1]heptanyl, or bicyclo[2.2.1]hept-2-enyl, bicyclo[ 1.1.1] pentanyl, but is not limited thereto.
- Cy 3 and Cy 4 can each independently be C 6 -C 10 aryl. In one embodiment, Cy 3 can be phenyl or naphthyl.
- Cy 3 and Cy 4 are each independently Cy 3 is a 5-10 membered monocyclic or bicyclic heteroaryl, a 5-10 membered monocyclic heterocycloalkyl, or a 5-10 membered monocyclic heterocycloalkyl. bicyclic bridged, fused or spiro heterocycloalkyl, wherein said 5- to 10-membered monocyclic heterocycloalkyl and 5- to 10-membered monocyclic heterocycloalkyl are optionally fused with C 3 -C 6 cycloalkyl.
- the 5-10 membered heteroaryl may contain 1 or 2 heteroatoms of N, O or S
- the 5-10 membered heterocycloalkyl may contain 1 of N, O or S. It may be a 5- or 6-membered heterocycloalkyl containing two heteroatoms.
- the 5- to 10-membered heteroaryl is indolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thia diazolyl, thiazolyl, isothiazolyl, imidazolyl, or triazolyl.
- the 5- or 6-membered heterocycloalkyl includes, but is not limited to, tetrahydropyranyl, piperidinyl, tetrahydrofuranyl, or tetrahydro 2H-thiopyranyl.
- the 5- to 10-membered heteroaryl or 5- to 10-membered heterocycloalkyl may optionally be fused with C 3 -C 6 cycloalkyl or C 3 -C 6 cycloalkenyl, such as cyclohexyl.
- This fused pyrazolyl, piperazine or tetrahydropyran can be formed.
- the 5- to 10-membered heterocycloalkyl can be a bicyclic bridged, fused or spiro heterocycloalkyl, such as 3-oxabicyclo[2.1.1]hexanyl or 2-oxabicyclo [2.1.1]hexanyl, but is not limited thereto.
- Cy 3 can be phenyl, naphthyl, pyridinyl, thiophenyl, tetrahydropyranyl or piperidine.
- B is -(CH 2 ) o -Cy 3 -W-Cy 4 , wherein Cy 3 and W are as described above, and Cy 4 can be phenyl or naphthyl. In one embodiment, Cy 3 and Cy 4 are each phenyl, and W may be a direct bond.
- B is -(CH 2 ) o -Cy 3 -W-Cy 4 wherein Cy 3 is 1 of C 3- C 6 cycloalkyl, C 3- C 6 cycloalkenyl, N, O or S 5- or 6-membered saturated or partially unsaturated heterocycloalkyl containing 2 or 2 heteroatoms, bridged bicyclic C 5-10 cycloalkyl, 5 containing 1 or 2 heteroatoms of N, O or S C 6 -C 10 aryl to which a 6-membered heterocycloalkyl is optionally fused, and 5- or 6-membered monocyclic heteroaryl containing 1 or 2 heteroatoms of N, O or S or 5-10 It may be selected from the group consisting of membered bicyclic heteroaryls.
- W may be NH, C(O) or a direct bond.
- Cy 4 is N, O, or S saturated or partially unsaturated 4- to 10-membered heterocycloalkyl containing one or two heteroatoms, C 6 -C 10 aryl, and one of N, O or S to 5- or 6-membered monocyclic heteroaryls containing 4 heteroatoms.
- the Cy 3 and Cy 4 may each independently be optionally substituted with 1 to 3 R 3 .
- the substituents that can be optionally substituted are as described above.
- Cy 3 may be optionally substituted with 1 to 3 R 3a
- Cy 4 is 1 to 3 optionally substituted with two R 3b .
- R 3a and R 3b are as described in Formula I below.
- One aspect of the present invention provides a compound, solvate, stereoisomer or pharmaceutically acceptable salt of Formula I:
- Z 1 is N or CH
- Z 1 is N
- Z 2 and Z 3 are both CHR 1 , is a single bond, or Z 2 and Z 3 are both CR 1 and is a double bond;
- Z 1 is CH
- Z 2 is N or CR 1
- Z 3 is CR 1
- Z 1 is N, Z 2 and Z 3 are both CR 1 , and is a double bond, two R 1s may optionally be linked to each other to form a thiophene or pyrrole ring together with the carbon atoms to which they are attached;
- R 1 is each independently H, halogen, CN, OH , NR b R c , C 1 -C 6 alkoxy, C 1 -C 6 acylamino, C 1 -C 6 alkylsulfonylamino, C 1 -C 6 alkyl , C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6- C 10 aryl, C 6- C 10 aryloxy, (C 6- C 10 aryl)-( selected from the group consisting of C 1 -C 6 alkyl)oxy and C 6 -C 10 arylamino;
- R' and R'' are each independently H or C 1 -C 3 alkyl, or R' and R'' together with the carbon atoms to which they are attached may form a C 3 -C 4 cycloalkyl, wherein the C 1 -C 3 alkyl and C 3 -C 4 cycloalkyl may be optionally substituted with one or more halogen, OH, CN, C 1 -C 3 alkoxy or NR b R c ;
- A is Cy 1 or Cy 1 -Y-Cy 2 ;
- Y is O, S, or a direct key
- Cy 1 is C 6 -C 10 aryl or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S;
- Cy 1 may be optionally substituted with 1 to 3 R 2a ;
- R 2a is H, halogen, OH, CN, oxo, SF 5 , NR b R c , -Si(C 1-3 alkyl) 3 , -SO 2 R b , -C(O)R b , C 1- C 6 alkyl, C 1- C 6 haloalkyl, C 1- C 6 alkoxy, C 1- C 6 haloalkoxy, C 3- C 6 cycloalkyl, and It is selected from the group consisting of,
- R 21 is H, halogen, OH, NR b R c , C 1 -C 6 alkoxy or C 1 -C 6 acyloxy, R 22 and R 23 are each independently H, halogen or C 1 -C 2 alkyl; ;
- Cy 2 is C 6 -C 10 aryl, phenyl fused with C 3 -C 6 cycloalkyl, or 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S;
- Cy 2 may be optionally substituted with 1 to 3 R 2b ;
- R 2b is H, halogen, OH, CN, oxo, NR b R c ; C 1- C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, CN, OH, NR b R c or C 1 -C 6 alkoxy; C 1 -C 6 alkyl optionally interrupted by 1 to 3 oxygen atoms and/or nitrogen atoms; and C 1 -C 6 alkyl substituted with hydroxy-(C 1 -C 6 alkyl)amino-;
- B is C substituted with H, C 1- C 6 alkyl, C 1- C 6 haloalkyl, C 1- C 6 hydroxyalkyl, C 1- C 6 alkoxy-C 1- C 6 alkyl, NR b R c 1- C 6 alkyl, -(CH 2 ) o -Cy 3 or -(CH 2 ) o -Cy 3 -W-Cy 4 ;
- W is NH, C(O) or a direct key
- o is an integer of 0 or 1;
- Cy 3 is C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, 5- or 6-membered saturated or partially unsaturated heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O and S; bridging bicyclic C 5-10 cycloalkyl, C 6 -C 10 aryl, phenyl fused with a 5- or 6-membered cyclic group containing 1 heteroatom selected from N, O and S, and N, O and S; is selected from the group consisting of 5- to 10-membered heteroaryls containing 1 to 3 heteroatoms selected from;
- Cy 3 may be optionally substituted with 1 to 3 R 3a ,
- R 3a is H, halogen, OH, CN, oxo, C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, OH, CN or C 1 -C 6 alkoxy; C 3 -C 6 Cycloalkyl, C 1- C 6 Alkoxy, C 1- C 6 Haloalkoxy, C 1- C 6 Haloalkylamino, C 1- C 6 Hydroxyalkylamino, (C 3 -C 6 Cycloalkyl ) carbonylamino, -NR b R c , -NR b COR c , -NR b C(O)OR c , -SO 2 R b , -C(O)R b , -C(O)OR b , -NR b SO 2 R c and -CONR b1 R c1 ;
- Cy 4 is a saturated or partially unsaturated 4- to 10-membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O or S, C 6 -C 10 aryl, and 1 selected from N, O and S; to 5- or 6-membered heteroaryls containing 4 heteroatoms;
- Cy 4 may be optionally substituted with 1 to 3 R 3b ;
- R 3b is H, deuterium, halogen, OH, CN, oxo, NR b R c , C 1- C 6 alkyl, C 1- C 6 alkyl substituted with deuterium, C 1- C 6 haloalkyl, C 1- C 6 hydroxyalkyl, C 1- C 6 alkoxy-C 1- C 6 alkyl, C 1- C 6 alkoxy or C 1- C 6 haloalkoxy;
- R b and R c are each independently H or C 1 -C 6 alkyl
- R b1 and R c1 is H or C 1 -C 6 alkyl
- the other of R b1 and R c1 is H, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with NR b R c ; or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxy.
- both Z 2 and Z 3 are CR 1 and may be a double bond. Further, both Z 2 and Z 3 are CHR 1 , may be a single bond.
- Z 1 is N
- Z 2 and Z 3 are both CR 1
- two R 1s may optionally be linked to each other to form a thiophene or pyrrole ring with the carbon atom to which they are attached.
- Z 1 when Z 1 is CH, Z 2 is N or CR 1 , Z 3 is CR 1 , may be a double bond.
- R 1 in Formula I is each independently selected from H, halogen, CN, OH, NR b R c , C 1 -C 6 alkoxy, C 1 -C 6 acylamino, C 1 -C 6 alkylsulfonylamino, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6- C 10 aryl, C 6- C 10 aryloxy, (C 6- C 10 aryl)-(C 1 -C 6 alkyl)oxy and C 6 -C 10 arylamino.
- R b and R c are each independently H or C 1 -C 6 alkyl.
- each R 1 may independently be H, halogen, CN, OH or C 1 -C 6 alkoxy.
- R 1 may be a substituted or unsubstituted amino group such as NR b R c , C 1 -C 6 acylamino, C 1 -C 6 alkylsulfonylamino, or C 6 -C 10 arylamino.
- R 1 may be a hydrocarbon group such as C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl.
- R 1 is a ring substituent such as C 3 -C 6 cycloalkyl, C 6 -C 10 aryl, C 6 -C 10 aryloxy or (C 6 -C 10 aryl)-(C 1 -C 6 alkyl)oxy.
- both R 1 s substituted on the same ring may be H.
- R 1 is H, F, Br, Cl, I, CN, OH, OCH 3 , amino, methylamino, dimethylamino, ethylamino, acetylamino, methylsulfonylamino, ethylsulfonylamino, methyl, ethyl, ethenyl, ethynyl, cyclopropyl, cyclobutyl, cyclopentyl, phenyl, phenoxy, benzyloxy or phenylamino.
- R' and R′′ are each independently H or C 1 -C 3 alkyl, or R' and R′′ together with the carbon atom to which they are attached form a C 3 -C 4 cycloalkyl. can do.
- the C 1 -C 3 alkyl and C 3 -C 4 cycloalkyl may be substituted with one or more halogen, OH, CN, C 1 -C 3 alkoxy or NR b R c .
- R b and R c are each independently H or C 1 -C 6 alkyl.
- R′ and R′′ may each independently be H or C 1 -C 3 alkyl.
- R' and R'' optionally together with the carbon atoms to which they are attached, may form a cyclopropane ring, in which case, in Formula A Is can be
- R' and R'' may be the same or different from each other, and when R' and R'' are different, the carbon to which they are bonded is a chiral center, and the compound of Formula I has stereoisomers, Any such stereoisomers are also included within the scope of the present invention.
- R' and R'' are H, in Formula I Is or (R''' is C 1 -C 3 alkyl, such as methyl or ethyl).
- Formula I of the present invention can be a compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, represented by Formula IA:
- A may be Cy 1 .
- Cy 1 can be C 6 -C 10 aryl or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S.
- Cy 1 can be C 6 -C 10 aryl, or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N and S. In one embodiment, Cy 1 can be phenyl, naphthalenyl, thiophenyl or pyridinyl.
- Cy 1 can have any of the following ring structures optionally substituted with 1 to 3 R 2a : .
- Cy 1 when A is Cy 1 , Cy 1 may be optionally substituted with 1 to 3 R 2a .
- Cy 1 may be substituted with 1, 2 or 3 R 2a .
- R 2a is H, halogen, OH, CN, oxo, SF 5 , NR b R c , -Si(C 1-3 alkyl) 3 , -SO 2 R b , -C(O)R b , C 1- C 6 alkyl, C 1- C 6 haloalkyl, C 1- C 6 alkoxy, C 1- C 6 haloalkoxy, C 3- C 6 cycloalkyl, and is selected from the group consisting of, R 21 is H, halogen, OH, NR b R c , C 1- C 6 alkoxy or C 1- C 6 acyloxy, R 22 and R 23 are each independently H, halogen or C 1 - C 2 alkyl. In this case, R b and R c may each independently be H or C 1 -C 6 alkyl.
- each R 2a is independently H, F, Cl, Br, I, OH, CN, SF 5 , -Si(CH 3 ) 3 , CH 3 SO 2 -, methyl, ethyl, propyl, isopropyl. , CF 3 , CHF 2 , CH 2 F, NH 2 , CH 3 NH 2 -, (CH 3 ) 2 N-, methoxy, ethoxy, OCF 3 , OCHF 2 , OCH 2 F, cyclopropyl, cyclobutyl, cyclopentyl, , , , , , , , and It may be selected from the group consisting of, but is not limited thereto.
- a in Formula I of the present invention may be selected from the following structures:
- a in Formula I can be selected from the following structures:
- a in Formula I is or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the same or can be any organic compound having the amine
- A may be Cy 1 -Y-Cy 2 .
- Y may be O, S, or a direct bond.
- Y can be O or a direct bond.
- Y may be a direct bond.
- Cy 1 is C 6 -C 10 aryl, or 5-6 membered heteroaryl containing 1 to 3 heteroatoms of N, O or S.
- Cy 1 can be C 6 -C 10 aryl, or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N, O and S. In one embodiment, it may be a C 6 -C 10 aryl, or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N and S.
- Cy 1 can include phenyl, naphthalenyl, thiazolyl, thiophenyl or pyrazolyl.
- Cy 2 when A is Cy 1 -Y-Cy 2 , Cy 2 is C 6 -C 10 aryl, C 6 -C 10 aryl fused with C 3 -C 6 cycloalkyl, or N, O or S It may be a 5- to 6-membered heteroaryl containing 1 to 3 heteroatoms. In one embodiment, Cy 2 is C 6 -C 10 aryl, phenyl fused with C 3 -C 6 cycloalkyl, or 5- or 6-membered group containing 1 or 2 heteroatoms selected from N, O and S may be heteroaryl.
- Cy 2 is C 6 -C 10 aryl, phenyl fused with C 3 -C 5 cycloalkyl, or 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N and S.
- Cy 2 is phenyl, 2,3-dihydroindenyl or bicyclo[4.2.0]octa-1,3,5-trienyl, pyrazolyl, thiophenyl, pyridinyl, 2-oxo-1 ,2-dihydropyridinyl or pyrrolyl.
- Cy 1 is C 6 -C 10 aryl, or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N and S;
- Y is O or a direct key;
- Cy 2 can be C 6 -C 10 aryl, phenyl fused with C 3 -C 5 cycloalkyl, or 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N and S.
- Cy 1 is phenyl and Cy 2 is phenyl, pyrroleyl, pyrazolyl, thiophenyl, pyridinyl, or 2-oxo-1,2- It may be dihydropyridinyl.
- Y may be O or a direct bond.
- Y can be a direct bond.
- Cy 1 is phenyl, Y is O, and Cy 2 can be phenyl or pyridinyl.
- Cy 1 is thiazolyl, thiophenyl or pyrazolyl and Cy 2 is phenyl, 2,3-dihydroindenyl or bicyclo[4.2.0]octa-1,3,5-triene it can be a day
- Cy 1 can be thiophenyl and Cy 2 can be phenyl.
- Cy 1 -Y-Cy 2 may have the following ring structure optionally substituted with R 2a and R 2b :
- each of Cy 1 and Cy 2 may be optionally substituted with 1 to 3 R 2 .
- R 2 are each independently H, halogen, OH, CN, oxo, SF 5 , -Si(C 1- C 3 alkyl) 3 , C 1- C 6 alkylsulfonyl, C 1- C 6 alkylcarbon mono, amino, C 1- C 6 alkylamino, di(C 1- C 6 alkyl)amino; optionally substituted with halogen, CN, OH, C 1- C 6 alkoxy, amino, C 1- C 6 alkylamino, di(C 1- C 6 alkyl)amino or hydroxy-(C 1 -C 6 alkyl)amino- C 1 - C 6 alkyl; C 1- C 6 alkoxy, C 1- C 6 haloalkoxy, C 3- C 6 cycloalkyl and It may be selected from the group consisting of.
- R 21 is H, halogen, OH, C 1- C 6 alkoxy, C 1- C 6 acyloxy, amino, C 1- C 6 alkylamino or di(C 1- C 6 alkyl)amino
- R 22 and R 23 may each independently be H, halogen or C 1 -C 2 alkyl.
- Cy 1 when A is Cy 1 -Y-Cy 2 , Cy 1 may be optionally substituted with 1 to 3 R 2a .
- R 2a is H, halogen, OH, CN, oxo, SF 5 , NR b R c , -Si(C 1-3 alkyl) 3 , -SO 2 R b , -C(O)R b , C 1- C 6 alkyl, C 1- C 6 haloalkyl, C 1- C 6 alkoxy, C 1- C 6 haloalkoxy, C 3- C 6 cycloalkyl and It may be selected from the group consisting of.
- R 21 is H, halogen, OH, NR b R c , C 1- C 6 alkoxy or C 1- C 6 acyloxy
- R 22 and R 23 are each independently H, halogen or C 1- C 2 alkyl
- Cy 1 is optionally substituted with 1 R 2a
- R 2a is H, halogen, OH, CN, amino, C 1- C 6 alkyl, C 1- C 6 haloalkyl, C 1- C 6 alkoxy or C 1 -C 6 haloalkoxy.
- R 2a can include H, halogen, OH or CN.
- R 2a can be H or halogen.
- R 2a can be H.
- Cy 2 when A is Cy 1 -Y-Cy 2 , Cy 2 may be optionally substituted with 1 to 3 R 2b .
- Cy 2 may be optionally substituted with 1 to 3 R 2b .
- R 2b is H, halogen, OH, CN, oxo, NR b R c ; C 1- C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, CN, OH, NR b R c or C 1 -C 6 alkoxy; C 1 -C 6 alkyl optionally interrupted by 1 to 3 oxygen atoms and/or nitrogen atoms; and C 1 -C 6 alkyl substituted with hydroxy-(C 1 -C 6 alkyl)amino-.
- each R 2b is independently H, F, Cl, Br, I, OH, CN, oxo, amino, CH 3 NH-, (CH 3 ) 2 N-, (CH 3 ) 2 NCH 2 - methyl, ethyl , cyanomethyl, hydroxymethyl, aminomethyl, CH 3 NHCH 2 -, C 2 H 5 NHCH 2 - or HOC 2 H 4 NHCH 2 -, but is not limited thereto.
- R 2b is H, halogen, C 1 -C 6 alkyl; or C 1 -C 6 alkyl substituted with amino, C 1 -C 6 alkylamino or di(C 1 -C 6 alkyl )amino.
- a in Formula I of the present invention may be selected from the following structures:
- a in Formula I can be selected from the following structures:
- B is H, C 1- C 6 alkyl, C 1- C 6 haloalkyl, C 1- C 6 hydroxyalkyl, C 1- C 6 alkoxy-C 1- C 6 alkyl, or C 1 -C 6 alkyl substituted with NR b R c .
- Rb and Rc are each H or C 1 -C 6 alkyl.
- B is H, CH 3 , or can be
- B may be -(CH 2 ) o -Cy 3 .
- o may be 0 or 1.
- Cy 3 is C 3- C 8 cycloalkyl, C 3- C 8 cycloalkenyl, N, O, and 1 selected from S or 1 heteroatom selected from 5- or 6-membered saturated or partially unsaturated heterocycloalkyl containing 2 heteroatoms, bridged bicyclic C 5-10 cycloalkyl, C 6 -C 10 aryl, N, O and S It may be selected from the group consisting of phenyl fused with a 5- or 6-membered cyclic group including, and 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S.
- Cy 3 is C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkenyl, 6-membered saturated or partially unsaturated heterocycloalkyl containing 1 N, O or S, bridged bicyclic C 5-8 cycloalkyl, C 6 -C 10 aryl, phenyl fused with 5-membered heterocycloalkyl containing 1 N, O or S, 5-membered containing 1 or 2 heteroatoms of N or S, or 6-membered heteroaryls and 9- or 10-membered bicyclic heteroaryls containing 1 to 3 N atoms.
- Cy 3 is C 3- C 6 cycloalkyl, C 3- -C 6 cycloalkenyl, tetrahydropyranyl, dihydropyranyl, thianyl, 1,1-dioxothianyl, piperidinyl, di hydropyridinyl, tetrahydropyridinyl, bicyclo[1.1.1]pentanyl, bicyclo[2.2.1]heptanyl, C 6-10 aryl, thiophenyl, thiazolyl, pyrazolyl, pyridinyl, pyrimi It may be dinyl, dihydroisobenzofuranyl, indolyl, indazolyl or benzotriazolyl, but is not limited thereto.
- the Cy 3 may include any one of the following ring structures, which may be optionally substituted with R 3a :
- Said Cy 3 may be optionally substituted with 1 to 3 R 3a ,
- R 3a is H, halogen, OH, CN, oxo, C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, OH, CN or C 1 -C 6 alkoxy;
- R b and R c may each independently be H or C 1 -C 6 alkyl.
- one of Rb1 and Rc1 is H or C 1- C 6 alkyl
- the other one of Rb1 and Rc1 is H, C 1- C 6 alkyl, C 1- C 6 substituted with NR b R c alkyl, or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxy.
- R 3a is H, F, Cl, Br, I, OH, CN, oxo, methyl, ethyl, amino, CH 3 NH-, (CH 3 ) 2 NH-, 1,1,1-trifluoropropane -2-ylamino, CH 3 CONH-, (CH 3 CO)(CH 3 )N-, CH 3 OCONH-, cyclopropylcarbonylamino, hydroxymethyl, 1-hydroxyethyl, 2-hydroxypropane- 2-yl, methoxy, ethoxy, isopropoxy, methoxymethyl, 2-methoxyethyl, OCHF 2 , OCF 3 , CH 3 SO 2 -, CH 3 CO-, CH 3 SO 2 NH-, -COOH , -COOC(CH 3 ) 3 , -CONH 2 , -CONHCH 3 , -CONHC 2 H 5 , -CON(CH 3 ) 2 , -CONHC 2 H 4 OCH 3
- B in Formula I of the present invention may be selected from the following structures:
- B is It may be selected from, but is not limited thereto.
- B is or It may be, but is not limited thereto.
- B may be -(CH 2 ) o -Cy 3 -W-Cy 4 .
- o may be 0 or 1.
- W may be NH, C(O) or a direct bond.
- Cy 3 is 1 or 2 selected from C 3- C 8 cycloalkyl, C 3- C 8 cycloalkenyl, N, O and S 5- or 6-membered saturated or partially unsaturated heterocycloalkyl containing 1 heteroatom, bridged bicyclic C 5-10 cycloalkyl, C 6 -C 10 aryl, containing 1 heteroatom selected from N, O and S phenyl in which a 5- or 6-membered cyclic group is fused, and a 5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O and S.
- Cy 3 can be C 6 -C 10 aryl, or a 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N or S.
- Cy 4 is a saturated or partially unsaturated 4- to 10-membered heterocycle containing 1 or 2 heteroatoms selected from N, O or S; alkyl, C 6 -C 10 aryl, and 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms selected from N, O and S.
- Cy 4 is saturated or partially unsaturated 4-7 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O or S, C 6 -C 10 aryl, and N, O and It may be selected from the group consisting of 5- or 6-membered heteroaryls containing 1 to 4 heteroatoms selected from S.
- B is -(CH 2 ) o -Cy 3 -W-Cy 4 and Cy 3 can be phenyl or pyridinyl.
- Cy 4 is oxetanyl, tetrahydrofuranyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, morpholinyl, imidazolidinyl, 2-oxo-imidazolidinyl, piperazine 1, 2-oxo-piperazinyl, hexahydropyrimidinyl, 2-oxo-hexahydropyrimidinyl, phenyl, oxazolyl, isoxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, tria zolyl, tetrazolyl, pyridinyl or 2-oxo-pyridinyl.
- Cy 3 is phenyl and Cy 4 can be pyrazolyl, imidazolyl, triazolyl or tetrazolyl.
- Cy 3 may be phenyl and Cy 4 may be triazolyl.
- Cy 3 may be pyridinyl and Cy 4 may be triazolyl.
- W can be NH, C(O) or a direct bond.
- W may be a direct bond.
- Cy 3 is C 6 -C 10 aryl
- Cy 4 is a saturated or partially unsaturated 4-7 membered heterocycloalkyl containing 1 or 2 heteroatoms selected from N, O or S
- W can be NH or C(O).
- Cy 3 -W-Cy 4 may include any one of the following ring structures, and rings corresponding to Cy 3 and Cy 4 may be optionally substituted with R 3a and R 3b , respectively:
- the Cy 3 and Cy 4 may each independently be optionally substituted with 1 to 3 R 3 .
- R 3 independently substituted by Cy 3 and Cy 4 is H, deuterium, halogen, OH, CN, oxo, C 1- C 6 alkyl, deuterium substituted C 1- C 6 alkyl, C 1- C 6 haloalkyl, C 1- C 6 hydroxyalkyl, C 1- C 6 alkoxy-C 1- C 6 alkyl, C 1- C 6 Alkoxy, C 1- C 6 Haloalkoxy, C 1- C 6 Haloalkylamino, (C 3 -C 6 cycloalkyl)carbonylamino, -NR b R c , -NR b COR c , -NR b C(O ) OR c , -SO 2 R b , -C(O)R b , -C(O)OR b , -NR b SO 2 R c , or -CONR b1 R
- R b and R c may each independently be H or C 1 -C 6 alkyl.
- one of R b1 and R c1 is H or C 1- C 6 alkyl, and the other is H, C 1- C 6 alkyl; or C 1 -C 6 alkyl substituted with amino, C 1 -C 6 alkylamino, di(C 1 -C 6 alkyl)amino or C 1 -C 6 alkoxy .
- Cy 3 may be optionally substituted with 1 to 3 R 3a .
- R 3a is H, halogen, OH, CN, oxo, C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, OH, CN or C 1 -C 6 alkoxy; C 3 -C 6 Cycloalkyl, C 1- C 6 Alkoxy, C 1- C 6 Haloalkoxy, C 1- C 6 Haloalkylamino, C 1- C 6 Hydroxyalkylamino, (C 3 -C 6 Cycloalkyl ) carbonylamino, -NR b R c , -NR b COR c , -NR b C(O)OR c , -SO 2 R b , -C(O)R b , -C(O)OR b , -NR b SO 2 R c , and -CONR b1 R c1 .
- R b and R c are each independently H or C 1 -C 6 alkyl; One of R b1 and R c1 is H or C 1 - C 6 alkyl, the other of R b1 and R c1 is H, C 1 - C 6 alkyl, C 1 - C 6 alkyl substituted with NR b R c , or C 1 -C 6 alkyl substituted with C 1 -C 6 alkoxy.
- the Cy 3 may be optionally substituted with 1 or 2 R 3a .
- R 3a can be H, halogen, OH, CN, oxo, amino, C 1- C 6 alkyl, C 1- C 6 haloalkyl or C 1- C 6 haloalkoxy.
- R 3a includes, but is not limited to, H, halogen, OH or CN.
- R 3a may be H or F, but is not limited thereto.
- R 3a can be H.
- R 3b is H, deuterium, halogen, OH, CN, oxo, NR b R c , C 1- C 6 alkyl, C 1- C 6 alkyl substituted with deuterium, C 1- C 6 haloalkyl, C 1- C 6 hydroxyalkyl, C 1- C 6 alkoxy-C 1- C 6 alkyl, C 1- C 6 alkoxy or C 1- C 6 haloalkoxy.
- R b and R c are H or C 1 -C 6 alkyl.
- R 3b includes, but is not limited to, H, deuterium, halogen, OH, CN, oxo, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with deuterium, or C 1 -C 6 haloalkyl. .
- R 3b can be H or C 1 -C 6 alkyl.
- R 3b includes, but is not limited to, H, F, oxo, methyl, ethyl, CHF 2 and CD 3 .
- R 3b can be H or methyl.
- Cy 3 may be optionally substituted with 1 or 2 R 3a , R 3a is H, halogen, OH or CN; Cy 4 may be optionally substituted with 1 to 3 R 3b , R 3b is H, deuterium, halogen, OH, CN, oxo, C 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with deuterium, or C 1 -C 6 haloalkyl.
- B in Formula I may be selected from the following structures:
- B can be selected from the following structures:
- B is It may be, but is not limited thereto.
- Formula I of the present invention may be represented by any one of the following I-1, I-2, I-3, I-4, I-5, I-6, I-7:
- each R 1 may be the same or different.
- the compound of Formula I can be a compound selected from the group:
- a numerical range expressed using the term “to” refers to a range including the numerical values described before and after the term “to” as the lower limit and the upper limit, respectively.
- the terms “optional” or “optionally” mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. means that As an example, the term “optionally substituted” is meant to include both unsubstituted and substituted cases with specified substituents.
- alkyl refers to a fully saturated branched or unbranched (or straight chain or linear) hydrocarbon.
- the alkyl may be a substituted or unsubstituted alkyl group.
- the alkyl may be arbitrarily interrupted by one or more oxygen atoms or nitrogen atoms, and the alkyl group interrupted by the oxygen atom or nitrogen atom refers to an alkyl group in which an oxygen atom or nitrogen atom is inserted between carbon atoms of the alkyl chain.
- an alkyl interrupted by an oxygen atom or a nitrogen atom includes alkoxyalkyl, alkylaminoalkyl, and the like, and includes a case where an oxygen atom or a nitrogen atom is located at the end of a substituent, such as hydroxyalkyl or aminoalkyl.
- the C 1 -C 6 alkyl may be an alkyl group of C 1 to C 6 , C 1 to C 5 , C 1 to C 4 , C 1 to C 3 , or C 1 to C 2 .
- Non-limiting examples of the alkyl may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, n-pentyl, isopentyl, neopentyl, iso-amyl, or n-hexyl. there is.
- alkenyl refers to a straight-chain or branched-chain hydrocarbon group having 2 to 6 carbon atoms, 2 to 5 carbon atoms, or 2 to 4 carbon atoms and having one or more double bonds at any position.
- vinyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, etc. can be heard
- alkynyl refers to a hydrocarbon group containing at least one triple bond, and includes straight-chain or branched-chain alkynyl having 2 to 6 carbon atoms, 2 to 5 carbon atoms, or 2 to 4 carbon atoms. Examples include ethynyl, propynyl, butynyl, pentynyl, and hexynyl.
- alkoxy refers to a substituent in which a substituted or unsubstituted straight-chain or branched-chain alkyl moiety is linked to another chemical structure by an oxygen.
- the alkoxy may include, without limitation, all possible isomers thereof such as, for example, methoxy, ethoxy, propoxy, and butoxy, or isopropoxy, isobutoxy, and t-butoxy.
- cycloalkyl refers to a saturated hydrocarbon ring having a specified number of carbon atoms as ring elements (i.e., C 3 -C 8 cycloalkyl has 3, 4, 5, 6, 7 or 8 carbon atoms as ring elements). Refers to a cycloalkyl group having a carbon atom).
- the cycloalkyl may be C 3 -C 6 monocyclic or C 5 -C 20 polycyclic (eg bicyclic, tricyclic or tetracyclic).
- monocyclic cycloalkyl can be C 3 -C 6 , C 3 -C 5 , or C 3 -C 4 cycloalkyl.
- Monocyclic cycloalkyls can be, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- a bicyclic, tricyclic or tetracyclic cycloalkyl can be C 5 -C 18 cycloalkyl, C 5 -C 15 cycloalkyl, C 5 -C 11 cycloalkyl, C 5 -C 10 cycloalkyl.
- Polycyclic cycloalkyl may be one in which two or more cycloalkyls are bridged, fused or spiro bonded, and in tricyclic or tetracyclic cycloalkyl each cycloalkyl ring is bridged or fused. And spiro bonding may be combined in two or more forms.
- polycyclic bridged, fused or spiro cycloalkyls are bicyclo[1.1.1]pentanyl, bicyclo[2.2.2]octanyl, adamantyl, bicyclo[2.2.1]heptanyl, bicyclo[ 3.1.0]hexanyl, bicyclo[3.2.0]heptanyl, bicyclo[3.2.1]octanyl, bicyclo[3.3.1]octanyl, bicyclo[3.3.0]octanyl, bicyclo[ 4.2.0] octane, spiro[2.3]hexanyl, spiro[2.4]heptanyl, spiro[3.3]heptanyl, spiro[2.5]octanyl, spiro[3.4]octanyl, octahydro-1H-indenyl, deca hydronaphthalenyl and the like.
- cycloalkyl may optionally include fused heteroaryl or heterocycloalkyl (e.g., cyclohexyl fused with pyrazole, piperazine or tetrahydropyran), in which case heteroaryl or heterocycloalkyl Cycloalkyl is as defined below.
- heteroaryl or heterocycloalkyl e.g., cyclohexyl fused with pyrazole, piperazine or tetrahydropyran
- cycloalkenyl refers to a non-aromatic unsaturated monocyclic or polycyclic hydrocarbon ring having at least one carbon-carbon double bond and containing the specified number of carbon atoms.
- monocyclic cycloalkenyl includes, but is not limited to, cyclopent-1-en-1-yl, cyclohex-1-en-1-yl, cyclohex-1,3-dien-1-yl, and the like. It doesn't work.
- bicyclic, tricyclic or tetracyclic cycloalkyl The matters concerning the number of carbon atoms and bonding type of the bicyclic, tricyclic or tetracyclic cycloalkyl are equally applicable to the bicyclic, tricyclic or tetracyclic cycloalkenyl.
- bicyclic, tricyclic or tetracyclic cycloalkenyl includes those in which a carbon-carbon double bond is introduced at any position in the bicyclic, tricyclic or tetracyclic cycloalkyls exemplified above.
- cycloalkenyl may optionally include heteroaryl or heterocycloalkyl fused thereto (e.g., cyclohexenyl fused with pyrazole, piperazine or tetrahydropyran), in which case heteroaryl or heterocycloalkyl is as defined below.
- aryl refers to a monocyclic or polycyclic aromatic hydrocarbon group.
- the aryl is an alternating double bond (resonance) between adjacent carbon atoms or suitable heteroatoms, and may include a simple pendant or condensed form of two or more rings.
- the aryl may be, for example, C 6 -C 10 aryl, or C 6 -C 9 aryl, for example, without limitation, phenyl, naphthalenyl (naphthyl), toluyl, or all possible isomers thereof.
- Aryl herein may be fused with cycloalkyl.
- a C 6-10 aryl can be fused with a 3- to 8-membered cycloalkyl.
- phenyl and cyclobutyl are fused to form bicyclo[4.2.0]octa-1,3,5-trienyl, or phenyl and cyclopentyl are fused to form 2,3-dihydroindenyl.
- aryl may optionally be fused with heterocycloalkyl.
- a C 6-10 aryl can be fused with a 5-10 membered heterocycloalkyl.
- phenyl and tetrahydrofuranyl can be fused to form dihydrobenzofuranyl or dihydroisobenzofuranyl.
- the heteroaryl may also include a form in which two or more rings are simply pendant or condensed with each other.
- the heteroaryl may include 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom selected from N, O and S.
- the heteroaryl may contain 5 to 10, or 5 to 6 ring atoms.
- Examples of monocyclic heteroaryls include thiophenyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and similar groups, but are not limited thereto.
- bicyclic heteroaryls include indolyl, isoindolyl, indazolyl, indolizinyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzthia Zolyl, benzisothiazolyl, benzthiadiazolyl, benztriazolyl, quinolinyl, isoquinolinyl, quinoxaline, quinazoline, purinyl, phthalazinyl, pteridinyl, furopyridinyl, oxochromene, dioxoi soindoline, imidazopyridinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, pyrazolopyridinyl, and similar groups.
- heteroaryl optionally includes one having a cycloalkyl group fused thereto (eg, pyrazolyl fused with cyclohexyl).
- it may include pyridinoneyl (pyridonyl), pyridazinoneyl, pyrimidinonyl (pyrimidonyl), pyrazinonyl, and the like.
- the N, B or P of the heteroaryl may be linked to another moiety.
- a monocyclic or polycyclic saturated or partially unsaturated ring system i.e., 3- to 7-membered heterocycloalkyl is a heterocycloalkyl group having 3, 4, 5, 6 or 7 ring members, including heteroatoms).
- Polycyclic heterocycloalkyls may include two or more heterocycloalkyl rings simply pendant from each other, bridged or condensed, or may also include a spiro form.
- the heterocycloalkyl may contain 1 to 4 heteroatoms selected from N, O and S, 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom.
- the heterocycloalkyl may include 5 to 10, 4 to 7, 5 or 6 ring atoms.
- the heterocycloalkyl group is, but is not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrroline, dihydrofuran, tetrahydrofuranyl (oxanyl), dihydrothiophenyl, tetrahydrothio Ofenyl, sulfolanyl, thianyl, dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, thiazolidinyl, isothiazolinyl, isothia Zolidinyl, oxazolinyl, oxazolidinyl, isoxazolinyl, isoxazolidinyl, triazolinyl, triazolidinyl, tetrazolinyl, tetrazolidiny
- heterocycloalkyl optionally includes a cycloalkyl group fused thereto (eg, piperidinyl fused with cyclohexyl).
- a heterocycloalkyl includes N, B or P in the ring, the N, B or P of the heterocycloalkyl may be linked to another moiety.
- halogen refers to an atom belonging to group 17 of the periodic table.
- Halogen atoms include fluorine, chlorine, bromine, iodine, and the like, and may be used interchangeably with the term “halo,” which refers to a monovalent functional group composed of halogen.
- cyano is -CN and refers to a functional group consisting of a triple bond between a carbon atom and a nitrogen atom.
- hydroxy refers to an -OH functional group (hydroxyl group).
- oxy refers to a divalent functional group of -O-.
- acyl refers to a functional group in which the carbon at position 1 of alkyl is substituted with oxo, and includes “formyl” and "alkylcarbonyl".
- C 1-6 acyl is C 1-6 alkyl as carbon at position 1 is substituted with oxo, formyl (HC (O)-), acetyl (CH 3 C (O)-), propion One (CH 3 CH 2 C(O)-), Butanoyl (CH 3 CH 2 CH 2 C(O)-), Pentanoyl (CH 3 CH 2 CH 2 CH 2 CO-), Hexanoyl (CH 3 CH 2 CH 2 CH 2 CH 2 C(O)-) and the like.
- acyloxy refers to a functional group in which acyl is bonded to one end of oxy, and includes “formyloxy” and "alkylcarbonyloxy".
- C 1-3 acyloxy may include formyloxy, acetyloxy (acetoxy), propionyloxy, and the like.
- sulfonyl refers to a divalent functional group of -S(O) 2 -.
- C 1-6 alkylsulfonyl may include methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, hexylsulfonyl, and the like.
- amino means -NH 2 .
- alkylamino refers to a functional group in which one hydrogen of amino is replaced with an alkyl.
- C 1-6 alkylamino may include, without limitation, methylamino, ethylamino, propylamino, butylamino, and the like as -NH(C 1- C 6 alkyl).
- dialkylamino refers to a functional group in which each of the two hydrogens of amino is substituted with an alkyl.
- the substituted alkyls may be the same as or different from each other.
- di(C 1-6 alkyl)amino is -N(C 1- C 6 alkyl) 2 as dimethylamino, diethylamino, dipropylamino, dibutylamino, ethylmethylamino, methylpropylamino, ethyl propylamino and the like may be included without limitation.
- acylamino refers to a functional group in which the carbon at position 1 of alkyl in alkylamino is substituted with oxo, and includes “formylamino” and “alkylcarbonylamino”.
- carbamoyl refers to -CONH 2 .
- alkylcarbamoyl refers to a functional group in which one hydrogen of carbamoyl is substituted with alkyl.
- C 1-6 alkylcarbamoyl is -CONH (C 1-6 alkyl) -CONHCH 3 , -CONHCH 2 CH 3 , -CONHCH 2 CH 2 CH 3 , -CONHCH 2 CH 2 CH 2 CH 3 , etc. may include, but are not limited to.
- dialkylcarbamoyl refers to a functional group in which two hydrogens of carbamoyl are each substituted with alkyl.
- C 1-6 alkylcarbamoyl is -CON(C 1-6 alkyl) 2 as -CON(CH 3 ) 2 , -CON(CH 2 CH 3 ) 2 , -CON(CH 3 )(CH 2 CH 3 ) and the like may be included without limitation.
- a "substituted" group is one in which one or more hydrogen atoms are replaced with one or more non-hydrogen atoms, provided that valence requirements are satisfied and chemically stable compounds result from the substitution.
- substituents are to be construed as being capable of being substituted or unsubstituted.
- an “optionally substituted” referred to without limitation of a specific substituent may encompass a moiety that is unsubstituted or substituted with any substituent.
- an “optionally substituted” moiety can refer to a moiety substituted with the following substituents:
- C 3 -C optionally substituted with one or more substituents selected from the group consisting of halogen, OH, CN, oxo, NH 2 , NH(C 1- C 6 alkyl) and N(C 1- C 6 alkyl) 2 6 cycloalkyl.
- solvate may refer to a compound of the present invention or a salt thereof containing a stoichiometric or non-stoichiometric solvent bound by non-covalent intermolecular forces.
- Preferred solvents in this regard may be solvents that are volatile, non-toxic, and/or suitable for administration to humans.
- stereoisomer may mean a compound of the present invention or a salt thereof having the same chemical formula or molecular formula but optically or sterically different, specifically, diastereomers, enantiomers , or may be a geometric isomer.
- compounds of the present invention may contain one or more asymmetric centers and may be in the form of racemates, single enantiomers, mixtures of enantiomers, single diastereomers, mixtures of diastereomers, and the like. In one embodiment, due to the nature of the asymmetric center or limited rotation, the compounds of the present invention may exist in enantiomeric or diastereomeric forms.
- the compound of the present invention may be used in the form of a pharmaceutically acceptable salt derived from an inorganic or organic acid, for example, the salt is hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, Lonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methane It may be a salt derived from sulfonic acid, benzenesulfonic acid or toluenesulfonic acid or the like.
- a pharmaceutically acceptable salt of the above compound is obtained by dissolving the compound of formula I in a water-miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile, and adding an excess organic acid or an acid aqueous solution of an inorganic acid, followed by precipitation. or by crystallization. Then, after evaporating the solvent or excess acid from this mixture, it may be dried to obtain an addition salt, or the precipitated salt may be suction filtered.
- a water-miscible organic solvent such as acetone, methanol, ethanol, or acetonitrile
- the compounds according to the present invention can be prepared through chemical modifications well known to those skilled in the art of organic/medicinal chemistry according to the methods shown representatively below.
- the following general reaction scheme generally illustrates a representative method for preparing the compound of formula I, and for those skilled in the art, starting materials suitable for the desired compound, reaction temperature, reaction conditions,
- the compound of formula (I) can be readily prepared by appropriately selecting a catalyst, solvent, treatment method, and the like.
- the representation of each substituent of Formula I in Reaction Schemes 1 to 9 is the same as that of the substituent at the corresponding position in Formula I, unless otherwise limited.
- the same variables are defined identically, and repeated definitions are omitted.
- the compound of Formula I can be prepared by reacting intermediate a and intermediate b according to the method of Scheme 1 below.
- na and nb are each independently an appropriate integer that satisfies the number of R 2 and R 3 defined in Formula I above.
- the compound of Formula I may be prepared by combining intermediate compound a with intermediate compound b through an amide coupling reaction using HATU.
- R 2 is a NO 2 group
- the compound of Formula I having an NH 2 substituent on ring B may be prepared by reduction with an NH 2 group under reducing reaction conditions.
- reaction reagent used in Scheme 1 may change to various reagents for carrying out the amide coupling reaction based on common knowledge in the related field, and accordingly, reaction conditions such as appropriate reaction time and reaction temperature you will be able to choose
- reaction conditions such as appropriate reaction time and reaction temperature you will be able to choose
- intermediates a and b can be reacted in HATU, TEA and DMF at about 20 ° C to about room temperature for about 2 hours to about 3 hours.
- intermediates a and b can be reacted in HATU, DIEA and DMF at about 10 ° C. to about 30 ° C. for about 2 hours to about 15 hours.
- intermediates a and b can be reacted in EDCI, HOBT, DMAP and DCM at about 10 ° C. to about 20 ° C. for about 10 hours to about 15 hours.
- intermediates a and b can be reacted in TEA, HOBT, EDCI and DCM at about 20 ° C. to about 30 ° C. for about 2 hours to about 5 hours.
- intermediates a and b can be reacted in DIEA, HOBT, EDCI and DMF at about 15 ° C. to about 25 ° C. for about 2 hours to about 15 hours.
- compounds of Formula I can be prepared according to the reaction of Scheme 1A below.
- R' is an alkyl
- compounds of Formula I can be prepared according to the reaction of Scheme 1B below.
- R B is alkyl optionally substituted with, for example, halogen, hydroxy, alkoxy, amino, alkylamino, dialkylamino, aryl or cycloalkyl.
- R B may be introduced into the nitrogen atom by reacting a compound prepared according to Scheme 1A with a halide of R B .
- a compound of Formula I can be prepared according to the method of Scheme 1C below.
- a 1 and A 2 are structures corresponding to Cy 1 and Cy 2 in Formula I, respectively.
- a pinacolborane compound is synthesized by coupling a starting material in which Ring A 1 is halogenated with bis(pinacolato)diborane under an appropriate catalyst (eg, Pd(dppf)Cl 2 ). Then, it can be coupled with a halide of ring A 2 to prepare a compound of formula I.
- an appropriate catalyst eg, Pd(dppf)Cl 2
- compounds of Formula I can be prepared according to the method of Scheme 1D below.
- a starting material in which ring A 1 is halogenated is coupled with a pinacolborane or boronic acid derivative of ring A 2 under an appropriate catalyst (eg, Pd(dppf)Cl 2 ) to obtain a compound of formula I.
- an appropriate catalyst eg, Pd(dppf)Cl 2
- compounds of Formula I can be prepared according to the method of Scheme 1E below.
- a pinacolborane compound is synthesized by coupling a starting material in which ring B 1 is halogenated with bis(pinacolato)diborane under an appropriate catalyst (eg, Pd(dppf)Cl 2 ) , which can be coupled with halogenated derivatives of ring B 2 to prepare compounds of formula I.
- an appropriate catalyst eg, Pd(dppf)Cl 2
- a compound of Formula I can be prepared according to the method of Scheme 1F below.
- a starting material in which ring B 1 is halogenated is coupled with a pinacolborane or boronic acid compound of ring B 2 under a suitable catalyst (eg, Pd(dppf)Cl 2 ) to obtain a compound of formula I.
- a suitable catalyst eg, Pd(dppf)Cl 2
- the R 1 group of Formula I may be introduced after intermediate b is coupled with intermediate a.
- a suitable halogenated intermediate a to which ring B is bonded is prepared in a suitable solvent (eg DCM, toluene) in the presence of a suitable catalyst (eg AlMe 3 ) if necessary.
- a suitable catalyst eg AlMe 3
- CuCN in an appropriate solvent eg N-methyl-2-pyrrolidone
- R is H or alkyl.
- intermediate a in which R 1 is substituted can be prepared according to the method of Scheme 2A below.
- R is H or alkyl.
- an appropriate halogenated intermediate a to which ring B is bonded may be reacted with a boronic acid compound of R 1 to prepare intermediate a into which R 1 is introduced.
- intermediate a wherein R 1 is alkyl
- Scheme 2B Scheme 2B
- a suitable halogenated intermediate a to which ring B is bonded in the presence of a suitable catalyst eg, Pd(PPh 3 ) 4 , Pd(dppf)Cl 2 , etc.
- Intermediate a in which an alkyl group is introduced as R 1 may be prepared by reacting with (Zn Negishi reaction).
- intermediate a can be prepared according to the method of Scheme 3 below.
- an appropriate starting material is dissolved in a solvent (eg DCM), an appropriate amount of base (eg pyridine) and Cu(OAc) 2 are added, followed by a boronic acid of ring B or 4,4,5,5-tetramethyl- Intermediate a can be prepared by reacting with a 1,3,2-dioxaborolane (pinacolborane) derivative and hydrolyzing the ester groups by adding an appropriate base (eg LiOH).
- intermediate a can be prepared according to the method of Scheme 4 below.
- X a is halogen, methylsulfonyloxy or trifluoromethylsulfonyloxy.
- an appropriate starting material is dissolved in a solvent (eg DMF), an appropriate amount of base (eg K 2 CO 3 ) is added, and then reacted with a halide, methylsulfonate or trifluoromethylsulfonate derivative of Ring B;
- Intermediate a can be prepared by hydrolysis of the ester group by the addition of an appropriate base (eg LiOH).
- intermediate a can be prepared according to the method of Scheme 5 below.
- an appropriate starting material is dissolved in a solvent (eg DMF), an appropriate amount of DMEDA, K 3 PO 4 , CuI is added, followed by reaction with a ring B halide compound, and an appropriate base (eg LiOH) is added to form an ester group.
- a solvent eg DMF
- intermediate a can be prepared according to the method of Scheme 6 below.
- R i and R ii are each alkyl.
- a mixture of an aminated Ring B compound, water and HCl is treated with NaNO 2 and added to NaOAc and 3-oxopentanedioate in an appropriate solvent (eg EtOH, water) to form a hydrazone compound; Stirring in an appropriate solvent (eg 1,2-dichlorobenzene) forms a hydroxyl-substituted dihydropyridazinone ring. Then, a trifluoromethylsulfonyloxy group is introduced by adding Tf 2 O in an appropriate solvent (eg, DCM), and reacted with a boronic acid compound as R 1 to prepare intermediate a.
- an appropriate solvent eg 1,2-dichlorobenzene
- intermediate a can be prepared according to the method of Scheme 6A below.
- intermediate a by reacting a hydrazinated ring B compound and 2-oxopentanedioate in the presence of MeOH and HCl to form a hydrazone compound, followed by stirring in NaOMe and MeOH to form a tetrahydropyridazinone ring. can be manufactured.
- intermediate a can be prepared according to the method of Scheme 6B below.
- a hydroxy-substituted dihydropyridazinone ester compound is sequentially reacted with POCl 3 and NaN 3 to change the hydroxyl group to an azido group via a chloro group, and reduce the azido group under a Pd/C catalyst.
- Intermediate a with an amino group introduced as R 1 can be prepared.
- intermediate a can be prepared according to the method of Scheme 6C below.
- an iodo group may be introduced by reacting intermediate a prepared according to Scheme 6B with NIS, and a compound having a trimethylsilylethynyl group introduced by coupling with ethynyl(trimethyl)silane may be synthesized. Thereafter, intermediate a having a pyrrolodihydropyridazinone core may be prepared through a cyclization reaction under NaH and NMP conditions.
- intermediate a can be prepared according to the method of Scheme 6D below.
- a 3-oxopentanedioate compound can be reacted with 1,4-dithiane-2,5-diol in the presence of LiBr to form a thiophene diester compound.
- the thiophene diester compound is reacted with SeO 2 in anisole solvent to further introduce an oxo group into the thiophene diester compound, and after cyclization with hydrazine, it is reacted with a boronic acid derivative of ring B to thienodihydropyridazinone.
- Intermediate a can be prepared with a core.
- intermediate a can be prepared according to the method of Scheme 6E below.
- a brominated thiophene ester compound is reacted with oxalate in the presence of n-BuLi to synthesize a thiophene oxodiester compound, and then reacted with a hydrazine-substituted ring B compound to thienodihydropyridazinone.
- Intermediate a can be prepared with a core.
- intermediate a wherein R 1 is alkyl
- R 1 is alkyl
- the trifluoromethylsulfonyloxy group prepared by the method of Scheme 6 is introduced into a suitable solvent (eg, THF, dioxane, etc.) in an appropriate catalyst (eg, Pd(PPh 3 ) 4 , Pd(dppf)Cl 2 , etc.) ) in the presence of dialkyl zinc (Zn Negishi reaction) to introduce an alkyl group into the dihydropyridazinone ring, followed by hydrolysis of the ester group by adding an appropriate base (eg LiOH) to prepare intermediate a.
- a suitable solvent eg, THF, dioxane, etc.
- an appropriate catalyst eg, Pd(PPh 3 ) 4 , Pd(dppf)Cl 2 , etc.
- dialkyl zinc Zn Negishi reaction
- intermediate a can be prepared according to the method of Scheme 7A below.
- a compound having a trifluoromethylsulfonyloxy group introduced therein is reacted with DPPP and Et 3 SiH in a suitable solvent (eg DMF) in the presence of an appropriate catalyst (eg Pd(OAc) 2 ) to obtain trifluoromethyl
- a suitable solvent eg DMF
- an appropriate catalyst eg Pd(OAc) 2
- intermediate a can be prepared according to the method of Scheme 8 below.
- intermediate a having a pyridinone core may be prepared by reacting a coumalate compound with an amine compound of ring B in the presence of pyridine.
- intermediate b can be prepared according to the method of Scheme 9 below.
- a halogenated ring A compound is reacted with 1-vinyloxybutane or tributyl(1-ethoxyvinyl)stannane under Heck reaction conditions, followed by treatment with an acid to obtain an acetylated ring A compound .
- the reaction may be performed in the presence of Pd(PP 3 ) 4 or Pd(PP 3 ) 2 Cl 2 , and a solvent such as TEA, butanol, or dioxane may be used.
- the acetylated ring A compound can then be reacted with tert-butyl sulfinamide having (R) orientation in the presence of titanium alkoxide, reducing the imine linkage to an amine linkage, and treating with an acid to produce intermediate b.
- intermediate b when R 2 is an alkylsilane group, intermediate b may be prepared according to the method of Scheme 10 below.
- R i , R ii and R iii are each an alkyl group, and two of R i , R ii and R iii may be optionally bonded to each other to form a cycloalkyl.
- a halogenated ring A compound can be introduced with an alkylsilane group on ring A using an appropriate alkyl silane halide compound in the presence of n-BuLi.
- Another aspect provides a pharmaceutical composition for preventing or treating SOS1 mediated diseases, comprising the compound of Formula I, a stereoisomer, a solvate, or a pharmaceutically acceptable salt thereof.
- the compounds of Formula I, stereoisomers, solvates, and pharmaceutically acceptable salts are as described above.
- preventing refers to preventing a disease, e.g., a disease in an individual who may be predisposed to the disease, condition, or disorder but has not yet experienced or exhibits pathology or signs of the disease. , to prevent a condition or disorder.
- treating refers to inhibiting a disease, e.g., inhibiting a disease, condition, or disorder in a subject experiencing or exhibiting pathology or symptoms of the disease, condition, or disorder, i.e. preventing further development of the pathology and/or symptom, or ameliorating the disease, e.g., ameliorating the disease, condition or disorder in a subject experiencing or exhibiting the pathology or symptom of the disease, condition or disorder i.e. , reversing pathology and/or symptoms, such as reducing disease severity.
- the SOS1-mediated diseases may include diseases that can be prevented or treated by inhibiting the interaction between SOS1 and RAS family proteins, or between SOS1 and RAC1.
- SOS1 mediated diseases may include diseases associated with abnormal activity of SOS1 and/or RAS family proteins.
- the SOS1 mediated disease may be, for example, cancer.
- Such cancers include, for example, pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, cervical cancer, endometrial cancer, thyroid cancer, chronic lymphocytic leukemia, acute myeloid leukemia, bladder cancer, urothelial cancer, stomach cancer, head and neck squamous cell carcinoma, diffuse large B cell lymphoma, esophageal cancer, hepatocellular cancer, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer or sarcoma.
- the cancer may be pancreatic cancer, lung cancer (eg, non-small cell lung cancer), cholangiocarcinoma or colorectal cancer.
- the cancer may be, for example, a cancer dependent on the RAS family and the MAPK signaling pathway.
- Such cancers include, for example, KRAS, NRAS, HRAS, receptor tyrosine kinases (e.g., EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A/B, FGFR1/2/3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC , RET, c-MET, VEGFR1/2/3, AXL), GAP (e.g. NF1) and mutations, gene amplification and/or overexpression of proteins or genes in the RAS family and MAPK signaling pathways (e.g. RAF, MEK mutation, amplification or overexpression of).
- the cancer may be a RAC1 dependent cancer.
- the SOS1 mediated disease may be, for example, a disease associated with dysregulation of the RAS family protein pathway, i.e. RASopathy.
- the RAS pathology is Neurofibromatosis type 1 (NF1), Noonan Syndrome, Noonan Syndrome with Multiple Lentigines (NSML), also called Leopard syndrome), capillary malformation-brain Capillary Malformation-Arteriovenous Malformation Syndrom (CM-AVM), Costello Syndrome, Cardio-Facio-Cutaneous Syndrome, Legius Syndrome (also called NF1-like syndrome), or hereditary Hereditary gingival fibromatosis.
- NF1 Neurofibromatosis type 1
- NML Noonan Syndrome with Multiple Lentigines
- CM-AVM capillary malformation-brain Capillary Malformation-Arteriovenous Malformation Syndrom
- Costello Syndrome Cardio-Facio-Cutaneous Syndrome
- Legius Syndrome also called NF1-like syndrome
- the compounds of the present invention may be used alone or in other anticancer therapies, such as radiation therapy, taxane derivatives (eg paclitaxel, docetaxel), platinum compounds (eg cisplatin, carboplatin), antimetabolites ( For example, 5-FU, gemcitabine, cytarabine), CDK4/6 inhibitors (eg, abemaciclib, palbociclib), immunotherapeutic agents (eg, anti-CTLA4 antibody, anti-PD1 antibody), angiogenesis inhibitors (eg, anti-CTLA4 antibody, anti-PD1 antibody) , bevacizumab), topoisomerase inhibitors (eg irinotecan), ERK inhibitors (eg ulixertinib), MDM2 inhibitors, PARP inhibitors, MCL-1 inhibitors, mTOR inhibitors (eg rapamycin, temsirolimus) , BET inhibitors, CDK9 inhibitors, IGF1/2 or IGF1-R inhibitors,
- the compound of Formula I inhibits the interaction between SOS1 and RAS family proteins, or between SOS1 and RAC1, to treat diseases associated with abnormal activity of SOS1 or RAS family proteins, or dysregulation of RAS family proteins pathways.
- SOS1 and RAS family proteins or between SOS1 and RAC1 to treat diseases associated with abnormal activity of SOS1 or RAS family proteins, or dysregulation of RAS family proteins pathways.
- the pharmaceutical composition may include conventional pharmaceutically acceptable carriers, excipients or additives.
- the pharmaceutical composition can be formulated according to conventional methods, and can be formulated in various oral dosage forms such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions, or parenteral dosage forms such as intramuscular, intravenous or subcutaneous administration. can be manufactured with
- the pharmaceutical composition may be a single composition or separate compositions.
- the pharmaceutical composition includes the compound, stereoisomer, solvate, or pharmaceutically acceptable salt according to one aspect as an active ingredient of the pharmaceutical composition.
- additives or carriers used include cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, stearic acid calcium, gelatin, talc, surfactants, suspending agents, emulsifying agents, diluents and the like.
- the additives or carriers include water, saline, aqueous glucose solution, similar aqueous sugar solution, alcohol, glycol, ether (eg polyethylene glycol 400), oil, fatty acid, fatty acid ester , glycerides, surfactants, suspending agents, emulsifying agents and the like.
- the dosage of the pharmaceutical composition is an amount effective for treatment or prevention of an individual or patient, and may be administered orally or parenterally as desired.
- oral administration it is administered in an amount of 0.01 to 1000 mg per 1 kg of body weight per day, more specifically, 0.1 to 300 mg per 1 kg of body weight per day based on the active ingredient when administered parenterally, per 1 kg of body weight per day based on the active ingredient.
- 0.01 to 100 mg, more specifically, 0.1 to 50 mg may be administered in one to several divided doses.
- the administration dose for a specific individual or patient should be determined in light of various related factors such as the patient's weight, age, sex, health condition, diet, administration time, administration method, and severity of disease, and can be appropriately increased or decreased by experts.
- the dosage is not intended to limit the scope of the present invention in any way.
- a physician or veterinarian having ordinary skill in the relevant art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- a physician or veterinarian may start with a dose of a compound of the present invention used in a pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. can increase
- the pharmaceutical composition includes within its scope a pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds according to one embodiment, alone or in combination with a pharmaceutical carrier.
- a pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds according to one embodiment, alone or in combination with a pharmaceutical carrier.
- therapeutically effective amount or “effective amount” means an amount sufficient to produce a beneficial or desired clinical result, eg, an amount sufficient to lessen, ameliorate, stabilize, reverse, slow or delay the progression of a disease.
- a compound according to one embodiment may be administered alone, in combination with a compound according to another embodiment, or concurrently, separately, or sequentially with one or more other therapeutic agents, such as anti-cancer agents or other pharmaceutically active substances.
- therapeutic agents such as anti-cancer agents or other pharmaceutically active substances.
- anticancer agents that can be co-administered are as described above.
- Another aspect provides a method for preventing or treating a SOS1 mediated disease comprising administering to a subject a compound of Formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition comprising the same. to provide.
- the administration may be oral or parenteral administration.
- oral administration it is administered in an amount of 0.01 to 1000 mg per 1 kg of body weight per day, more specifically, 0.1 to 300 mg per 1 kg of body weight per day based on the active ingredient when administered parenterally, per 1 kg of body weight per day based on the active ingredient. 0.01 to 100 mg, more specifically, 0.1 to 50 mg may be administered in one to several divided doses.
- the administration dose for a specific individual or patient should be determined in light of various related factors such as the patient's weight, age, sex, health condition, diet, administration time, administration method, and severity of disease, and can be appropriately increased or decreased by experts. there is.
- the term "individual” means a subject in need of treatment for a disease, and more specifically, mammals such as humans or non-human primates, mice, dogs, cats, horses, and cows. means
- Another aspect relates to the pharmaceutical use of a compound of Formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof for the prevention or treatment of SOS1 mediated diseases; or the use of a compound of formula (I), a solvate, stereoisomer or pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating an SOS1 mediated disease.
- the compound of formula I has an effective inhibitory activity against SOS1, and in particular inhibits the interaction between SOS1 and RAS family proteins, or between SOS1 and RAC1, thereby preventing SOS1 mediated diseases. , Specifically, it is useful for preventing or treating diseases associated with abnormal activity of SOS1 and/or RAS family proteins.
- Step 1 Synthesis of methyl 6-oxo-1-phenyl-pyridazine-3-carboxylate
- Phenylboronic acid (380 mg, 3.1 mmol), methyl 6-oxo-1H-pyridazine-3-carboxylate (504 mg), Cu(OAc) 2 (113 mg, 623 ⁇ mol), pyridine in DCM (10 mL) (1.6 g, 19.8 mmol)
- DCM 10 mL
- the reaction mixture was degassed, purged with N 2 3 times and then stirred under N 2 atmosphere at 20 ° C. for 16 h.
- the reaction mixture was poured into distilled water (20 mL) and extracted with EtOAc.
- Step 2 Synthesis of (R)-2-methyl-N-[1-[3-nitro-5-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide
- Step 3 Synthesis of (R)-2-methyl-N-[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide
- Step 1 Synthesis of ethyl 2-(3-acetylphenyl)-2,2-difluoro-acetate
- Step 2 Synthesis of ethyl 2-[3-[(Z)-N-[(R)-tert-butylsulfinyl]-C-methyl-carboimidoyl]phenyl]-2,2-difluoro-acetate
- Step 3 (R)-N-[(1R)-1-[3-(1,1-difluoro-2-hydroxy-ethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide synthesis of
- Step 3 Synthesis of ethyl 2-(3-acetyl-2-fluoro-phenyl)-2,2-difluoro-acetate
- Step 4 Ethyl 2-[3-[[(R)-tert-butylsulfinyl] - Synthesis of C-methyl-carboimidoyl]-2-fluoro-phenyl]-2,2-difluoro-acetate
- Step 1 Synthesis of methyl 5-bromo-6-oxo-1H-pyridazine-3-carboxylate
- Step 2 Synthesis of methyl 5-bromo-6-oxo-1-phenyl-pyridazine-3-carboxylate
- Step 2 Synthesis of methyl 4-hydroxy-6-oxo-1-phenylpyridazine-3-carboxylate
- Step 3 Synthesis of methyl 6-oxo-1-phenyl-4-(trifluoromethylsulfonyloxy)pyridazine-3-carboxylate
- Step 2 Synthesis of (R)-N-[1-(3-ethoxyphenyl)ethylidene]-2-methyl-propane-2-sulfinamide
- Step 3 Synthesis of (R)-N-[(1R)-1-(3-ethoxyphenyl)ethyl]-2-methyl-propane-2-sulfinamide
- Step 1 of Preparation Example 2 The starting materials and reagents of Step 1 of Preparation Example 2 were mixed with 1-bromo-3-pentafluoro- ⁇ 6 -sulfanylbenzene, tributyl(1-ethoxyvinyl)stannane, Pd(PPh 3 ) 2 Cl 2 and dioxane to obtain intermediate L in the same manner as steps 1 to 4 of Preparation Example 2.
- LC/MS (ESI) m/z 247.1 [M+H] + .
- Step 2 Synthesis of 1-[3-(dimethylcarbamoyl)-4-methoxy-phenyl]-6-oxo-pyridazine-3-carboxylic acid
- Methyl 6-oxo-1H-pyridazine-3-carboxylate (89.57 mg, 581.14 umol), 5-bromo-2-methoxy-N,N-dimethylbenzamide (100 mg, 387.43 umol), CuI (73.79 mg, 387.43 umol), (1R,2R)-N1,N2-dimethylcyclohexane
- a mixture of -1,2-diamine (110.22 mg, 774.86 umol) and K 2 CO 3 (160.64 mg, 1.16 mmol) was degassed and purged with N 2 three times, then the mixture was purged with N 2 at 90 ° C for 6 h. Stirred under atmosphere.
- Step 1 Synthesis of ethyl 2-[3-(1,1-dimethoxyethyl)-2-fluoro-phenyl]-2,2-difluoro-acetate
- Step 2 Synthesis of 1-[3-(1,1-dimethoxyethyl)-2-fluorophenyl]-1,1-difluoro-2-methyl-propan-2-ol
- Step 3 Synthesis of 1-[3-(1,1-dimethoxyethyl)-2-fluorophenyl]-1,1-difluoro-2-methyl-propan-2-ol
- Steps 4 to 6 Synthesis of (R)-1-(3-(1-aminoethyl)-2-fluorophenyl)-1,1-difluoro-2-methylpropan-2-ol
- Methyl 6-oxo-1H-pyridazine-3-carboxylate 150 mg, 973.25 ⁇ moL
- 5-bromo-2-methyl-thiazole 207.94 mg, 1.17 mmol
- CuI 18.54 mg, 97.32 ⁇ moL
- CsF 443.52 mg, 2.92 mmol
- (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine 27.69 mg, 194.60 ⁇ moL
- MeCN 3 mL
- Methyl 6-oxo-1H-pyridazine-3-carboxylate (150.99 mg, 979.65 ⁇ mol), 5-bromo-1,3-dihydroisobenzofuran (194.99 mg, 979.65 umol, 1.0 eq ), K 2 CO 3 (406.18 mg, 2.94 mmol), CuI (186.58 mg, 979.65 ⁇ mol) and (1S,2S)-N1,N2-dimethylcyclohexane-1,2-diamine (278.70 mg, 1.96 mmol) ) was degassed and purged with N 2 three times, and then the mixture was stirred at 100 ° C. for 16 h under N 2 atmosphere.
- Methyl 1-(3-bromo-4-methyl-phenyl)-6-oxo-pyridazine-3-carboxylate (100 mg, 309.46 umol), 1-methyltriazole (51.43 mg, 618.92 umol), K 2 CO 3 (85.54 mg, 618.92 umol), Pd(OAc) 2 (6.95 mg, 30.95 umol) and XPhos (29.51 mg, 61.89 umol) mixture was degassed and purged with N 2 three times, then , the mixture was stirred at 100 ° C for 12 h under N 2 atmosphere. The reaction mixture was poured into water (20 mL) and extracted with EtOAc (20 mL).
- Step 1 Synthesis of (NZ,S)-N-[1-(5-bromotiazol-2-yl)ethylidene]-2-methyl-propane-2-sulfinamide
- Step 2 Synthesis of (S)-N-[(1R)-1-(5-bromotiazol-2-yl)ethyl]-2-methylpropane-2-sulfinamide
- Steps 3 and 4 Synthesis of methyl 1-[3-(dimethylcarbamoyl)-2-fluoro-phenyl]-4-hydroxy-6-oxo-pyridazine-3-carboxylate
- Step 1 Synthesis of methyl 1-[3-(dimethylcarbamoyl)-2-fluoro-phenyl]-6-oxo-4-(trifluoromethylsulfonyloxy)pyridazine-3-carboxylate
- Step 2 Synthesis of methyl 1-[3-(dimethylcarbamoyl)-2-fluoro-phenyl]-6-oxo-pyridazine-3-carboxylate
- Methyl 1-[3-(dimethylcarbamoyl)-2-fluoro-phenyl]-6-oxo-4-(trifluoromethylsulfonyloxy)pyridazine-3-carboxylate (554 mg, 1.19 mmol), Pd(OAc) 2 (39.92 mg, 177.81 ⁇ moL), DPPP (146.67 mg, 355.62 ⁇ moL) and Et 3 SiH (179.19 mg, 1.54 mmol, 246.14 ⁇ L) was degassed and washed with N 2 3 After purging once, the mixture was stirred at 100 ° C. for 1 hour under N 2 atmosphere.
- Steps 1 and 2 Synthesis of 4-hydroxy-1-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Step 3 Synthesis of methyl 4-chloro-1-(1-methylpyrazol-4-yl)-6-oxo-pyridazine-3-carboxylate
- Step 4 Synthesis of methyl 4-azido-1-(1-methylpyrazol-4-yl)-6-oxo-pyridazine-3-carboxylate
- Step 5 Synthesis of methyl 4-amino-1-(1-methylpyrazol-4-yl)-6-oxopyridazine-3-carboxylate
- Methyl 4-azido-1-(1-methylpyrazol-4-yl)-6-oxo-pyridazine-3-carboxylate (4.2 g, 15.26 mmol) in MeOH (30 mL) and AcOH (30 mL) , Pd/C (1 g, 15.26 mmol, 10% purity) was degassed and purged with H 2 three times, then the mixture was stirred at 60 °C for 6 h under H 2 atmosphere.
- Step 6 Synthesis of methyl 4-amino-5-iodo-1-(1-methylpyrazol-4-yl)-6-oxo-pyridazine-3-carboxylate
- Methyl 4-amino-1-(1-methylpyrazol-4-yl)-6-oxo-pyridazine-3-carboxylate (4 g, 16.05 mmol), NIS (3.79 g, 16.85 mmol) was degassed and purged 3 times with N 2 , then the mixture was stirred at 20 °C for 3 h under N 2 atmosphere. The residue was filtered to obtain a residue. The residue was triturated with DCM (50 mL) for 30 min at 20 °C.
- Step 7 Synthesis of methyl 4-amino-1-(1-methylpyrazol-4-yl)-6-oxo-5-(2-trimethylsilylethynyl)pyridazine-3-carboxylate
- Methyl 4-amino-5-iodo-1-(1-methylpyrazol-4-yl)-6-oxo-pyridazine-3-carboxylate (900 mg, 2.40 mmol) in THF (5 mL), at of tinyl(trimethyl)silane (589.12 mg, 6.00 mmol), CuI (45.69 mg, 239.92 umol), TEA (728.32 mg, 7.20 mmol, 1.00 mL) and Pd(PPh 3 ) 2 Cl 2 (168.40 mg, 239.92 umol). After degassing the mixture and purging with N 2 three times, the mixture was stirred at 70 °C for 2 h under N 2 atmosphere.
- Step 8 Synthesis of 5-(1-methylpyrazol-4-yl)-4-oxo-1H-pyrrolo[2,3-d]pyridazine-7-carboxylic acid
- Steps 1 to 5 Synthesis of methyl 4-amino-6-oxo-1-phenyl-5-(2-trimethylsilylethynyl)pyridazine-3-carboxylate
- Methyl 4-hydroxy-6-oxo-1-phenyl-pyridazine-3-carboxylate obtained in step 2 of Preparation Example 8 was used as a starting material in the same manner as in Steps 3 to 7 of Preparation Example 30.
- Step 6 Synthesis of methyl 4-oxo-5-phenyl-1H-pyrrolo[2,3-d]pyridazine-7-carboxylate
- Step 1 Synthesis of ethyl 2-(2-ethoxy-2-oxo-ethyl)thiophene-3-carboxylate
- Step 2 Synthesis of ethyl 2-(2-ethoxy-2-oxoacetyl)thiophene-3-carboxylate
- Step 3 Synthesis of ethyl 4-oxo-5H-thieno[2,3-d]pyridazine-7-carboxylate
- Step 4 Synthesis of ethyl 4-oxo-5-phenyl-thieno[2,3-d]pyridazine-7-carboxylate
- Step 1 Synthesis of methyl 3-(2-ethoxy-2-oxo-acetyl)thiophene-2-carboxylate
- Step 2 Synthesis of ethyl 6-(2-fluorophenyl)-7-oxo-thieno[2,3-d]pyridazine-4-carboxylate
- Step 1 Synthesis of methyl 5-(tert-butoxycarbonylamino)-6-oxo-1-phenyl-pyridazine-3-carboxylate
- Step 2 Synthesis of methyl 5-amino-6-oxo-1-phenyl-pyridazine-3-carboxylate
- Step 1 Synthesis of methyl 4-(tert-butoxycarbonylamino)-1-(2-fluorophenyl)-6-oxo-pyridazine-3-carboxylate
- Step 2 Synthesis of methyl 4-[tert-butoxycarbonyl(methyl)amino]-1-(2-fluorophenyl)-6-oxo-pyridazine-3-carboxylate
- Step 1 Synthesis of methyl 1-(2,3-difluorophenyl)-6-oxo-1,6-dihydropyridine-3-carboxylate
- intermediates AQ-1, AQ-2, AQ-3 and AQ-4 were prepared in the same manner as in intermediate AQ.
- Step 1 Synthesis of methyl 1-(1-acetyl-4-piperidyl)-6-oxo-pyridazine-3-carboxylate
- Step 2 Synthesis of 1-(1-acetylpiperidin-4-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid
- Step 1 Synthesis of methyl 1-(3-formylphenyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
- Step 2 Synthesis of methyl 1-[3-(hydroxyiminomethyl)phenyl]-6-oxo-pyridazine-3-carboxylate
- Step 3 Synthesis of methyl 6-oxo-1-[3-(5-trimethylsilylisoxazol-3-yl)phenyl]pyridazine-3-carboxylate
- a solution of (hydroxyiminomethyl)phenyl]-6-oxo-pyridazine-3-carboxylate (100 mg, 365.97 umol) was added at 0 ° C and the mixture was stirred for 3 h.
- the reaction mixture was poured into water (50 mL) and extracted with EtOAc (50 mL ⁇ 3).
- Steps 2 to 4 (R)-N-[(1S)-1-[4-amino-6-(trifluoromethyl)-2-pyridyl]ethyl]-2-methyl-propane)-2-sulfin Synthesis of amides and (R)-N-[(1R)-1-[4-amino-6-(trifluoromethyl)-2-pyridyl]ethyl]-2-methyl-propane)-2-sulfinamide
Abstract
Description
실시예 No. | SOS-catalyzed nucleotide exchange assay | 실시예 No. | SOS-catalyzed nucleotide exchange assay |
1 | B | 81 | NA |
2 | B | 82 | NA |
3 | C | 83 | NA |
4 | B | 84 | NA |
5 | C | 85 | A |
6 | C | 86 | NA |
7 | C | 87 | NA |
8 | B | 88 | NA |
9 | B | 89 | A |
10 | B | 90 | NA |
11 | B | 91 | NA |
12 | C | 92 | NA |
13 | A | 93 | NA |
14 | B | 94 | A |
15 | A | 95 | A |
16 | A | 96 | A |
17 | B | 97 | B |
18 | B | 98 | NA |
19 | B | 99 | NA |
20 | A | 100 | NA |
21 | A | 101 | NA |
22 | A | 102 | NA |
23 | A | 103 | NA |
24 | B | 104 | NA |
25 | A | 105 | NA |
26 | A | 106 | NA |
27 | A | 107 | NA |
28 | C | 108 | NA |
29 | A | 109 | NA |
30 | A | 110 | NA |
31 | A | 111 | NA |
32 | A | 112 | NA |
33 | A | 113 | A |
34 | B | 114 | NA |
35 | A | 115 | B |
36 | A | 116 | B |
37 | A | 117 | B |
38 | A | 118 | B |
39 | A | 119 | C |
40 | A | 120 | B |
41 | A | 121 | NA |
42 | A | 122 | NA |
43 | A | 123 | NA |
44 | A | 124 | B |
45 | A | 125 | B |
46 | A | 126 | A |
47 | A | 127 | B |
48 | B | 128 | A |
49 | B | 129 | A |
50 | B | 130 | A |
51 | A | 131 | NA |
52 | B | 132 | NA |
53 | B | 133 | NA |
54 | A | 134 | NA |
55 | A | 135 | NA |
56 | A | 136 | NA |
57 | A | 137 | A |
58 | A | 138 | A |
59 | A | 139 | NA |
60 | C | 140 | A |
61 | B | 141 | A |
62 | A | 142 | A |
63 | B | 143 | A |
64 | B | 144 | B |
65 | A | 145 | NA |
66 | B | 146 | NA |
67 | A | 147 | NA |
68 | A | 148 | C |
69 | B | 149 | A |
70 | B | 150 | A |
71 | A | 151 | A |
72 | A | 152 | A |
73 | A | 153 | A |
74 | A | 154 | B |
75 | A | 155 | B |
76 | NA | 156 | B |
77 | NA | 157 | B |
78 | A | 158 | A |
79 | NA | 159 | A |
80 | NA | 160 | B |
실시예 No. | KRAS G12C ::SOS1 PPI assay | 실시예 No. | KRAS G12C ::SOS1 PPI assay |
140 | A | 278 | A |
141 | A | 279 | A |
142 | A | 280 | A |
143 | A | 281 | A |
144 | A | 282 | A |
145 | A | 283 | A |
146 | A | 284 | A |
147 | A | 285 | A |
148 | C | 286 | A |
149 | A | 287 | A |
150 | A | 288 | A |
151 | A | 289 | A |
152 | A | 290 | A |
153 | A | 291 | A |
154 | A | 292 | A |
155 | A | 293 | A |
156 | B | 294 | A |
157 | B | 295 | A |
158 | A | 296 | A |
159 | A | 297 | A |
160 | A | 298 | A |
161 | A | 299 | B |
162 | A | 300 | A |
163 | A | 301 | A |
164 | A | 302 | A |
165 | A | 303 | C |
166 | A | 304 | C |
167 | A | 305 | C |
168 | A | 306 | C |
169 | A | 307 | A |
170 | A | 308 | A |
171 | A | 309 | A |
172 | A | 310 | A |
173 | A | 311 | A |
174 | A | 312 | A |
175 | B | 313 | A |
176 | C | 314 | A |
177 | A | 315 | B |
178 | A | 316 | A |
179 | A | 317 | A |
180 | A | 318 | A |
181 | A | 319 | A |
182 | A | 320 | A |
183 | A | 321 | A |
184 | A | 322 | A |
185 | A | 323 | A |
186 | A | 324 | A |
187 | A | 325 | A |
188 | A | 326 | A |
189 | A | 327 | A |
190 | A | 328 | A |
191 | A | 329 | A |
192 | A | 330 | A |
193 | A | 331 | A |
194 | A | 332 | A |
195 | A | 333 | A |
196 | A | 334 | A |
197 | A | 335 | A |
198 | A | 336 | A |
199 | A | 337 | A |
200 | A | 338 | A |
201 | A | 339 | A |
202 | A | 340 | A |
203 | A | 341 | A |
204 | A | 342 | A |
205 | A | 343 | A |
206 | A | 344 | A |
207 | A | 345 | A |
208 | A | 346 | A |
209 | A | 347 | A |
210 | A | 348 | A |
211 | A | 349 | A |
212 | B | 350 | A |
213 | A | 351 | A |
214 | A | 352 | A |
215 | A | 353 | A |
216 | B | 354 | A |
217 | A | 355 | A |
218 | A | 356 | A |
219 | A | 357 | B |
220 | A | 358 | A |
221 | A | 359 | A |
222 | A | 360 | A |
223 | A | 361 | A |
224 | A | 362 | A |
225 | A | 363 | C |
226 | A | 364 | B |
227 | A | 365 | C |
228 | A | 366 | B |
229 | B | 367 | B |
230 | A | 368 | A |
231 | A | 369 | A |
232 | A | 370 | A |
233 | A | 371 | A |
234 | A | 372 | A |
235 | A | 373 | A |
236 | A | 374 | A |
237 | A | 375 | A |
238 | A | 376 | A |
239 | B | 377 | A |
240 | A | 378 | A |
241 | A | 379 | A |
242 | A | 380 | A |
243 | A | 381 | A |
244 | A | 382 | A |
245 | A | 383 | A |
246 | A | 384 | A |
247 | A | 385 | A |
248 | A | 386 | A |
249 | A | 387 | A |
250 | A | 388 | C |
251 | A | 389 | A |
252 | A | 390 | A |
253 | A | 391 | A |
254 | A | 392 | A |
255 | A | 393 | A |
256 | A | 394 | C |
257 | A | 395 | B |
258 | A | 396 | A |
259 | A | 397 | A |
260 | A | 398 | A |
261 | C | 399 | A |
262 | B | 400 | A |
263 | A | 401 | A |
264 | A | 402 | A |
265 | A | 403 | A |
266 | A | 404 | A |
267 | A | 405 | A |
268 | A | 406 | A |
269 | A | 407 | A |
270 | A | 408 | A |
271 | A | 409 | A |
272 | A | 410 | A |
273 | A | 411 | A |
274 | A | 412 | A |
275 | A | 413 | A |
276 | A | 414 | A |
277 | A | 415 | A |
Claims (48)
- 하기 화학식 I의 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염:[화학식 I]상기 화학식 I에서,Z1은 N 또는 CH이고;Z1이 N이고, Z2 및 Z3가 모두 CR1이고 은 이중 결합인 경우, 2개의 R1은 임의로 서로 연결되어 이들이 결합된 탄소 원자와 함께 티오펜 또는 피롤 고리를 형성할 수 있고;R1은 각각 독립적으로 H, 할로겐, CN, OH, NRbRc, C1-C6 알콕시, C1-C6 아실아미노, C1-C6 알킬설폰일아미노, C1-C6 알킬, C2-C6 알켄일, C2-C6 알킨일, C3-C6 사이클로알킬, C6-C10 아릴, C6-C10 아릴옥시, (C6-C10 아릴)-(C1-C6 알킬)옥시 및 C6-C10 아릴아미노로 구성된 군으로부터 선택되고;R' 및 R''는 각각 독립적으로 H 또는 C1-C3 알킬이거나, R' 및 R''은 이들이 결합된 탄소원자와 함께 C3-C4 사이클로알킬을 형성할 수 있고, 상기 C1-C3 알킬 및 C3-C4 사이클로알킬은 하나 이상의 할로겐, OH, CN, C1-C3 알콕시 또는 NRbRc로 임의로 치환될 수 있고;A는 Cy1 또는 Cy1-Y-Cy2이고;Y는 O, S, 또는 직접 결합이고;Cy1은 C6-C10 아릴, 또는 N, O 및 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴이고;Cy1은 1 내지 3개의 R2a로 임의로 치환될 수 있고;R2a는 H, 할로겐, OH, CN, 옥소, SF5, NRbRc, -Si(C1-3 알킬)3, -SO2Rb, -C(O)Rb, C1-C6 알킬, C1-C6 할로알킬, C1-C6 알콕시, C1-C6 할로알콕시, C3-C6 사이클로알킬 및 로 구성되는 군으로부터 선택되고,R21는 H, 할로겐, OH, NRbRc, C1-C6 알콕시 또는 C1-C6 아실옥시이고, R22 및 R23은 각각 독립적으로 H, 할로겐 또는 C1-C2 알킬이고;Cy2는 C6-C10 아릴, C3-C6 사이클로알킬과 융합된 페닐, 또는 N, O 및 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴이고;Cy2는 1개 내지 3개의 R2b로 임의로 치환될 수 있고;R2b는 H, 할로겐, OH, CN, 옥소, NRbRc; C1-C6 알킬; 할로겐, CN, OH, NRbRc 또는 C1-C6 알콕시로 치환된 C1-C6 알킬; 1개 내지 3개의 산소 원자 및/또는 질소 원자로 임의로 중단된 C1-C6 알킬; 및 하이드록시-(C1-C6 알킬)아미노-로 치환된 C1-C6 알킬로 구성된 군으로부터 선택되고;B는 H, C1-C6 알킬, C1-C6 할로알킬, C1-C6 하이드록시알킬, C1-C6 알콕시-C1-C6 알킬, NRbRc로 치환된 C1-C6 알킬, -(CH2)o-Cy3 또는 -(CH2)o-Cy3-W-Cy4이고;W는 NH, C(O) 또는 직접 결합이고;o는 0 또는 1의 정수이고;Cy3는 C3-C8 사이클로알킬, C3-C8 사이클로알켄일, N, O 및 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 5원 또는 6원 포화 또는 부분 불포화 헤테로사이클로알킬, 가교 바이사이클릭 C5-10 사이클로알킬, C6-C10 아릴, N, O 및 S로부터 선택된 1개의 헤테로원자를 포함하는 5원 또는 6원 사이클릭 기가 융합된 페닐, 및 N, O 및 S로부터 선택된 1개 내지 3개의 헤테로원자를 포함하는 5원 내지 10원 헤테로아릴로 구성된 군으로부터 선택되고;Cy3는 1 내지 3개의 R3a로 임의로 치환될 수 있고,R3a는 H, 할로겐, OH, CN, 옥소, C1-C6 알킬; 할로겐, OH, CN 또는 C1-C6 알콕시로 치환된 C1-C6 알킬; C3-C6 사이클로알킬, C1-C6 알콕시, C1-C6 할로알콕시, C1-C6 할로알킬아미노, C1-C6 하이드록시알킬아미노, (C3-C6 사이클로알킬)카본일아미노, -NRbRc, -NRbCORc , -NRbC(O)ORc , -SO2Rb, -C(O)Rb, -C(O)ORb, -NRbSO2Rc 및 -CONRb1Rc1로 구성된 군으로부터 선택되고;Cy4는 N, O 또는 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 포화 또는 부분 불포화 4원 내지 10원 헤테로사이클로알킬, C6-C10 아릴, 및 N, O 및 S 로부터 선택된 1개 내지 4개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴로 구성된 군으로부터 선택되고;Cy4는 1개 내지 3개의 R3b로 임의로 치환될 수 있고,R3b는 H, 중수소, 할로겐, OH, CN, 옥소, NRbRc, C1-C6 알킬, 중수소로 치환된 C1-C6 알킬, C1-C6 할로알킬, C1-C6 하이드록시알킬, C1-C6 알콕시-C1-C6 알킬, C1-C6 알콕시 또는 C1-C6 할로알콕시이고;Rb 및 Rc는 각각 독립적으로 H 또는 C1-C6 알킬이고;Rb1 및 Rc1 중 하나는 H 또는 C1-C6 알킬이고, Rb1 및 Rc1 중 나머지 하나는 H, C1-C6 알킬, NRbRc로 치환된 C1-C6 알킬, 또는 C1-C6 알콕시로 치환된 C1-C6 알킬이다.
- 제3항에 있어서,R1은 각각 독립적으로 H, F, Br, Cl, I, CN, OH, OCH3, 아미노, 메틸아미노, 디메틸아미노, 에틸아미노, 아세틸아미노, 메틸설폰일아미노, 에틸설폰일아미노, 메틸, 에틸, 에텐일, 에틴일, 사이클로프로필, 사이클로부틸, 사이클로펜틸, 페닐, 페녹시, 벤질옥시 및 페닐아미노로 구성된 군으로부터 선택되는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제4항에 있어서,동일 고리에 치환된 2개의 R1 중 하나는 H이고, 나머지 하나는 H가 아닌 것인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제4항에 있어서,동일 고리에 치환된 2개의 R1이 모두 H인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제1항에 있어서,R' 및 R''은 각각 H 또는 C1-C3 알킬이고, R' 및 R''은 임의로 이들이 결합한 탄소 원자와 함께 C3-C4 사이클로알킬을 형성할 수 있는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제1항에 있어서,A가 Cy1인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제11항에 있어서,Cy1은 C6-C10 아릴, 또는 N 및 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제12항에 있어서,A는 Cy1이고, Cy1은 페닐, 나프탈렌일, 티오펜일 또는 피리딘일인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제1항에 있어서,A가 Cy1-Y-Cy2인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제16항에 있어서,Cy1은 C6-C10 아릴, 또는 N 및 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴이고;Y는 O 또는 직접 결합이고;Cy2은 C6-C10 아릴, C3-C5 사이클로알킬과 융합된 페닐, 또는 N 및 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제17항에 있어서,Cy1은 페닐이고, Cy2는 페닐, 피롤일, 피라졸일, 티오펜일, 피리딘일, 또는 2-옥소-1,2-디하이드로피리딘일이거나, 또는Cy1은 티아졸일, 티오펜일 또는 피라졸일이고, Cy2는 페닐, 2,3-디하이드로인덴일 또는 바이사이클로[4.2.0]옥타-1,3,5-트리엔일인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제17항에 있어서,Y가 직접 결합인 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제16항에 있어서,Cy1은 1개의 R2a로 임의로 치환되고, R2a는 H, 할로겐, OH, CN, 아미노, C1-C6 알킬, C1-C6 할로알킬, C1-C6 알콕시 및 C1-C6 할로알콕시로 구성되는 군으로부터 선택되고;Cy2는 1개 내지 3개의 R2b로 임의로 치환되고, R2b는 H, 할로겐, OH, CN, 옥소, NRbRc; C1-C6 알킬; 할로겐, CN, OH, NRbRc 또는 C1-C6 알콕시로 치환된 C1-C6 알킬; 1개 내지 3개의 산소 원자 및/또는 질소 원자로 임의로 중단된 C1-C6 알킬; 및 하이드록시-(C1-C6 알킬)아미노-로 치환된 C1-C6 알킬로 구성된 군으로부터 선택되는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제21항에 있어서,R2a는 H인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제21항에 있어서,R2a는 H이고;R2b는 각각 독립적으로 H, F, Cl, Br, I, OH, CN, 옥소, 아미노, CH3NH-, (CH3)2N-, (CH3)2NCH2- 메틸, 에틸, 시아노메틸, 하이드록시메틸, 아미노메틸, CH3NHCH2-, C2H5NHCH2- 및 HOC2H4NHCH2-로 구성되는 군으로부터 선택되는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제1항에 있어서,B는 H, C1-C6 알킬, C1-C6 할로알킬, C1-C6 하이드록시알킬, C1-C6 알콕시-C1-C6 알킬, 또는 NRbRc로 치환된 C1-C6 알킬인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제1항에 있어서,B가 -(CH2)o-Cy3이고, o는 0 또는 1인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제26항에 있어서,Cy3는 C3-C8 사이클로알킬, C3-C8 사이클로알켄일, 1개의 N, O 또는 S를 포함하는 6원 포화 또는 부분 불포화 헤테로사이클로알킬, 가교 바이사이클릭 C5-8 사이클로알킬, C6-C10 아릴, 1개의 N, O 또는 S를 포함하는 5원 헤테로사이클로알킬이 융합된 페닐, N 또는 S 중 1개 또는 2개의 헤테로원자를 함유하는 5원 또는 6원 헤테로아릴 및 1개 내지 3개의 N을 포함하는 9원 또는 10원 바이사이클릭 헤테로아릴으로 구성된 군으로부터 선택되는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제27항에 있어서,Cy3는 C3-C6 사이클로알킬, C3--C6 사이클로알켄일, 테트라하이드로피란일, 디하이드로피란일, 티안일, 1,1-디옥소티안일, 피페리딘일, 디하이드로피리딘일, 테트라하이드로피리딘일, 바이사이클로[1.1.1]펜탄일, 바이사이클로[2.2.1]헵탄일, C6-10 아릴, 티오펜일, 티아졸일, 피라졸일, 피리딘일, 피리미딘일, 디하이드로이소벤조퓨란일, 인돌일, 인다졸일 또는 벤조트리아졸일인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제26항에 있어서,R3a는 H, F, Cl, Br, I, OH, CN, 옥소, 메틸, 에틸, 아미노, CH3NH-, (CH3)2NH-, 1,1,1-트리플루오로프로판-2-일아미노, CH3CONH-, (CH3CO)(CH3)N-, CH3OCONH-, 사이클로프로필카본일아미노, 하이드록시메틸, 1-하이드록시에틸, 2-하이드록시프로판-2-일, 메톡시, 에톡시, 이소프로폭시, 메톡시메틸, 2-메톡시에틸, OCHF2, OCF3, CH3SO2-, CH3CO-, CH3SO2NH-, -COOH, -COOC(CH3)3, -CONH2, -CONHCH3, -CONHC2H5, -CON(CH3)2, -CONHC2H4OCH3 및 -CONHC2H4N(CH3)2로 구성되는 군으로부터 선택되는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제1항에 있어서,B는 -(CH2)o-Cy3-W-Cy4이고, o는 0인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제31항에 있어서,Cy3는 C6-C10 아릴, 또는 N 또는 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴이고;W는 NH, C(O) 또는 직접 결합이고;Cy4는 N, O 또는 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 포화 또는 부분 불포화 4원 내지 7원 헤테로사이클로알킬, C6-C10 아릴, 및 N, O 및 S 로부터 선택된 1개 내지 4개의 헤테로원자를 포함하는 5원 또는 6원 헤테로아릴로 구성된 군으로부터 선택되는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제32항에 있어서,Cy3는 C6-C10 아릴이고, Cy4는 N, O 또는 S로부터 선택된 1개 또는 2개의 헤테로원자를 포함하는 포화 또는 부분 불포화 4원 내지 7원 헤테로사이클로알킬이고, W는 NH 또는 C(O)인 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제32항에 있어서,W는 직접 결합인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제32항에 있어서,Cy3는 페닐 또는 피리딘일이고;Cy4는 옥세탄일, 테트라하이드로퓨란일, 피롤리딘일, 2-옥소-피롤리딘일, 피페리딘일, 모르폴린일, 이미다졸리딘일, 2-옥소-이미다졸리딘일, 피페라진일, 2-옥소-피페라진일, 헥사하이드로피리미딘일, 2-옥소-헥사하이드로피리미딘일, 페닐, 옥사졸일, 이속사졸일, 티아졸일, 피라졸일, 이미다졸일, 옥사디아졸일, 트리아졸일, 테트라졸일, 피리딘일 또는 2-옥소-피리딘일인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제31항에 있어서,Cy3는 1개 또는 2개의 R3a로 임의로 치환될 수 있고, R3a는 H, 할로겐, OH 또는 CN이고;Cy4는 1개 내지 3개의 R3b로 임의로 치환될 수 있고, R3b는 H, 중수소, 할로겐, OH, CN, 옥소, C1-C6 알킬, 중수소로 치환된 C1-C6 알킬 또는 C1-C6 할로알킬인, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제37항에 있어서,R3a는 H 또는 F이고;R3b는 H, F, 옥소, 메틸, 에틸, CHF2 및 CD3로 구성되는 군으로부터 선택되는, 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염.
- 제1항 내지 제40항 중 어느 한 항의 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염을 유효성분으로 포함하는 약학 조성물.
- 제41항에 있어서,SOS1 매개된 질환의 예방 또는 치료를 위한 약학 조성물.
- 제42항에 있어서,상기 SOS1 매개된 질환이 암 또는 RAS병증인, 약학 조성물.
- 제43항에 있어서,상기 암은 췌장암, 폐암, 결장직장암, 담관암, 다발성 골수종, 흑색종, 자궁암, 자궁경부암, 자궁내막암, 갑상선암, 만성 림프구성 백혈병, 급성 골수성 백혈병, 방광암, 요로상피암, 위암, 두경부 편평세포 암종, 미만성 거대 B 세포 림프종, 식도암, 간세포암, 유방암, 난소암, 전립선암, 교모세포종, 신장암 및 육종으로 구성된 군으로부터 선택되는, 약학 조성물.
- 제43항에 있어서,상기 RAS병증이 신경섬유종증 1형(Neurofibromatosis type 1), 누난 증후군(Noonan Syndrome), 레오파드 증후군, 모세관 기형-뇌동정맥 기형 증후군(Capillary Malformation-Arteriovenous Malformation Syndrom), 코스텔로 증후군(Costello Syndrome), CFC 증후군(Cardio-Facio-Cutaneous Syndrome), 레기우스 증후군(Legius Syndrome) 및 유전성 치은 섬유증(Hereditary gingival fibromatosis)으로 구성된 군으로부터 선택되는, 약학적 조성물.
- 제1항 내지 제40항 중 어느 한 항의 화합물, 또는 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염을 개체에게 투여하는 단계를 포함하는 SOS1 매개된 질환의 예방 또는 치료하는 방법.
- SOS1 매개된 질환의 예방 또는 치료에 사용하기 위한 제1항 내지 제40항 중 어느 한 항에 따른 화합물, 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염의 용도.
- SOS1 매개된 질환을 예방 또는 치료하기 위한 의약을 제조하기 위한 제1항 내지 제40항 중 어느 한 항에 따른 화합물, 이의 용매화물, 입체이성질체 또는 약학적으로 허용가능한 염의 용도.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3229566A CA3229566A1 (en) | 2021-08-17 | 2022-08-17 | Sos1 inhibitor and use thereof |
AU2022330732A AU2022330732A1 (en) | 2021-08-17 | 2022-08-17 | Sos1 inhibitor and use thereof |
IL310872A IL310872A (en) | 2021-08-17 | 2022-08-17 | SOS1 inhibitor and its use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210108316 | 2021-08-17 | ||
KR10-2021-0108316 | 2021-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023022497A1 true WO2023022497A1 (ko) | 2023-02-23 |
Family
ID=85239600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/012254 WO2023022497A1 (ko) | 2021-08-17 | 2022-08-17 | Sos1 억제제 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20230026288A (ko) |
AU (1) | AU2022330732A1 (ko) |
CA (1) | CA3229566A1 (ko) |
IL (1) | IL310872A (ko) |
TW (1) | TW202328076A (ko) |
WO (1) | WO2023022497A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011557A2 (en) * | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
KR20150013563A (ko) * | 2012-04-24 | 2015-02-05 | 추가이 세이야쿠 가부시키가이샤 | 벤즈아미드 유도체 |
WO2019122129A1 (en) * | 2017-12-21 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
WO2021127429A1 (en) * | 2019-12-20 | 2021-06-24 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
-
2022
- 2022-08-17 IL IL310872A patent/IL310872A/en unknown
- 2022-08-17 AU AU2022330732A patent/AU2022330732A1/en active Pending
- 2022-08-17 WO PCT/KR2022/012254 patent/WO2023022497A1/ko active Application Filing
- 2022-08-17 KR KR1020220102624A patent/KR20230026288A/ko active Search and Examination
- 2022-08-17 TW TW111130992A patent/TW202328076A/zh unknown
- 2022-08-17 CA CA3229566A patent/CA3229566A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011557A2 (en) * | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
KR20150013563A (ko) * | 2012-04-24 | 2015-02-05 | 추가이 세이야쿠 가부시키가이샤 | 벤즈아미드 유도체 |
WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
WO2019122129A1 (en) * | 2017-12-21 | 2019-06-27 | Boehringer Ingelheim International Gmbh | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
WO2021127429A1 (en) * | 2019-12-20 | 2021-06-24 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
Non-Patent Citations (2)
Title |
---|
CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 62, 2021, pages 109 - 118 |
J. MED. CHEM., vol. 64, no. 10, 2021, pages 6569 - 6580 |
Also Published As
Publication number | Publication date |
---|---|
CA3229566A1 (en) | 2023-02-23 |
KR20230026288A (ko) | 2023-02-24 |
AU2022330732A1 (en) | 2024-02-15 |
TW202328076A (zh) | 2023-07-16 |
IL310872A (en) | 2024-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018270685C1 (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
WO2020190119A1 (ko) | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 | |
WO2010044543A2 (ko) | 단백질 키나제 억제제로서 헤테로사이클릭 화합물 | |
AU2016317806B2 (en) | Heteroaryl compounds and their use as therapeutic drugs | |
WO2020149723A1 (ko) | 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020235902A1 (ko) | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 | |
WO2021145521A1 (ko) | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 | |
WO2023282702A1 (ko) | Shp2 억제제 및 이의 용도 | |
WO2022131741A1 (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
WO2020185044A1 (ko) | 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 약학적 조성물 | |
WO2021261970A1 (ko) | 신규한 화합물 및 이를 포함하는 내성암 예방 또는 치료용 약학 조성물 | |
AU2021327622B2 (en) | Novel compounds having inhibitory activity on prostaglandin E2 receptor and uses thereof | |
WO2023022497A1 (ko) | Sos1 억제제 및 이의 용도 | |
WO2022270994A1 (ko) | 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도 | |
AU2019344240B2 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
WO2022177302A1 (ko) | Dna-pk 억제 활성을 갖는 피리미딘-융합 고리 화합물 및 이의 용도 | |
WO2019039905A1 (ko) | 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물 | |
WO2020106059A1 (ko) | Irak4 저해제로서 신규의 삼중고리 화합물 | |
WO2023158221A1 (ko) | 프로스타글란딘 e2 수용체에 대한 저해 활성을 갖는 신규 화합물 및 항암제를 포함하는 암 치료용 약학 조성물 | |
WO2023211256A1 (ko) | 신규한 pim 키나아제 억제 화합물 및 이의 용도 | |
WO2022235091A1 (ko) | 신규한 헤테로사이클 화합물 및 이의 용도 | |
WO2021086077A1 (ko) | 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022203399A1 (ko) | 아데노신 a2a 수용체 길항제 및 이의 용도 | |
WO2023121413A1 (ko) | 신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도 | |
WO2023229380A1 (ko) | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22858734 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022330732 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 807770 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401000941 Country of ref document: TH |
|
ENP | Entry into the national phase |
Ref document number: 2022330732 Country of ref document: AU Date of ref document: 20220817 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 310872 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3229566 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024002826 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2024106445 Country of ref document: RU Ref document number: 2022858734 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022858734 Country of ref document: EP Effective date: 20240318 |